TOTAL SYNTHESIS OF 6,7-DIMETHYL-N-METHYL AZIRIDINOMITOSENE

by
Thaaer N. Muhammed

A thesis
submitted in partial fulfillment
of the requirements for the degree of
Master of Science in Chemistry
Boise State University

May 2018

© 2018
Thaaer N. Muhammed
ALL RIGHTS RESERVED

BOISE STATE UNIVERSITY GRADUATE COLLEGE

DEFENSE COMMITTEE AND FINAL READING APPROVALS
of the thesis submitted by

Thaaer N. Muhammed

Thesis Title:

Total Synthesis of 6,7-Dimethyl-N-Methyl
Aziridinomitosene

Date of Final Oral Examination:

09 March 2018

The following individuals read and discussed the thesis submitted by student Thaaer N.
Muhammed, and they evaluated his presentation and response to questions during the final
oral examination. They found that the student passed the final oral examination.
Don Warner, Ph.D.

Chair, Supervisory Committee

Kenneth A. Cornell, Ph.D.

Member, Supervisory Committee

Eric Brown, Ph.D.

Member, Supervisory Committee

The final reading approval of the thesis was granted by Don Warner, Ph.D., Chair of the
Supervisory Committee. The thesis was approved by the Graduate College.

DEDICATION
I dedicate this work to my daughter (Zainab) and my family and friends. To all of
you that give me hope, encourage, and support. Thanks for always being there for me. I
will always appreciate all that you have done.

iv

ACKNOWLEDGEMENTS
I would like to express the deepest appreciation to my committee chair, Dr. Don
L. Warner for his time, help, understanding, wisdom, and the opportunity to work on his
research project. I would also like to thank the members of my committee, Dr. Ken
Cornell and Dr. Eric Brown for their time and support. Further, I would like to thank all
of my lab mates for their understanding and constant efforts to help me. I would like to
thank all the staff and faculty of the Department of Chemistry and Biochemistry at Boise
State University for their constant encouragement and support. Lastly, I would like to
thank all my family and my friends, here in Boise, and in Iraq for love and support.

v

ABSTRACT
Mitomycin C (MC) is a naturally occurring antitumor agent isolated from a soil
bacterium. MC is effective against solid hypoxic tumors that respond poorly to
radiotherapy, such as colorectal, gastric, and lung tumors. Also, it has a role in the treatment
of bladder, head and neck, and non-small cell lung cancers in combination with other
chemotherapeutic.
MC and other members of the mitomycin family of antitumor agents fight cancer
by forming DNA interstrand crosslinks (ICLs), which leads to apoptosis. In order to form
ICLs, MC requires a reductive activation step that produces reactive oxygen species. This
activation step is proposed to lead to adverse side effects, such as myelosuppression and
hemolytic uremic syndrome. Aziridinomitosenes (AZMs) are structurally related to MC
and are believed to form during in vivo reduction of MC. AZMs are relatively stable but
are more sensitive than the parent mitomycins due to an activated aziridine ring.
Consequently, AZMs do not require the reductive activation step in order to alkylate DNA.
The purpose of this work is to synthesize and study an AZM that is substituted with
methyl groups at two potential electrophilic sites. It is hypothesized that certain synthetic
AZMs crosslink DNA under non-reductive conditions as a result of a nucleophilic
activation sequence involving the quinone ring. To test this hypothesis, analogs were
prepared that would either reduce the rate of the activation step or prevent it from occurring.
The synthetic route starts with commercially available reagents to form an oxazole,
followed by the addition of a protected aldehyde that is converted to the required aziridine
vi

ring via a Mitsunobu reaction. Once the aziridine ring is formed, all of the reaction
conditions must be conducted using mild conditions in order to prevent ring-opening.
The completion of the synthesis and formation of the tetracyclic core was achieved
by performing an oxazolium salt/azomethine ylide [3+2] cycloaddition sequence. This
sequence was conducted multiple times, and the highest yield obtained was 44%. The final
steps were the most challenging, requiring several transformations to accomplish a
deprotection and oxidation to give a diketone that was oxidized to a quinone. Finally, the
carbamate was attached in two steps using FmocNCO to yield the desired AZM product in
an overall yield of 0.04% from the starting diol over the 22 step reaction sequence. The
stability of the AZM was tested in buffered methanolic solutions, and the results were
compared to other aziridinomitosenes. While unsubstituted AZMs decompose in basic
solutions, the C6/C7 dimethyl AZM showed high stability under these conditions.
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1

CHAPTER ONE: MITOMYCIN C: ISOLATION AND ANTICANCER PROPERTIES
Mitomycins are a family of natural antibiotic, anticancer agents that were
discovered in the 1950s by Hata and coworkers from fermentation cultures of the soil
bacterium Streptomyces caespitosus.1 An important member of this family is mitomycin
C (Figure 1.1), which was isolated from the fermentation broth of the same bacteria in
1958 by Wakaki and coworkers.2 The original structure, assigned in 1963 by chemical
degradation and spectrophotometric analysis, was shown to contain a unique tetracyclic
core with an aziridine ring fused to a pyrrolo[1,2-a] indole system, as well as an
aminobenzoquinone.3 The absolute configuration was revised in 1983 to that shown in
Figure 1-1, following studies using X-ray dispersion techniques.4 The methylated analog
of MC was isolated from Streptomyces verticillatus, and named poriformycin (2, Figure
1.1).3,5

Figure 1.1

Structures of Mitomycin C and Poriformycin.

An early in vivo bioactivity study found that MC has good antitumor activity with
an effective dose range between 8-1000 μg/kg, and the LD50 values were found to be
5000 μg /kg in mice.1,2 Also, it was found that hypoxic cancer cells are sensitive to MC at

2
low doses,6 while non-hypoxic cancer cells and non-cancerous cells are sensitive at
higher doses.7
Clinical Use of Mitomycin C
In 1960, MC was introduced into clinical trials in Japan after a case study of 351
patients treated demonstrated a tumor response rate of 37%.8 In the U.S.A., the drug was
approved by the Food and Drug Administration (FDA) in 1974, and the new drug
application (NDA) included “usefulness in the treatment of many kind of cancers”.9 MC
is effective against hypoxic solid tumors that respond poorly to radiotherapy,6 and is
effective against colorectal, gastric and lung tumors when used in monotherapy.
Historically, MC has a role in the treatment of bladder, head and neck, and nonsmall-cell lung cancers.8,10 MC has been shown to covalently bond to complementary
DNA strands to form interstrand crosslinks (ICLs), and other adducts, which prevent
DNA replication and cause cancer cell death.11 However, MC requires intracellular
enzymatic reduction to activate it in order to covalently bond to DNA.12
Bioreduction of MC produces reactive oxygen species that lead to adverse side
effects, such as myelosuppression and hemolytic uremic syndrome.13,14 While these side
effects have minimized its clinical use, MC is still active as a single agent in localized
treatment of bladder cancer. MC has also found applications in other medicinal fields. It
has been used as an antimetabolite therapy in eye surgery to prevent scarring during
wound healing, and to promote continuous open filtration to decrease intraocular
pressure. In pterygium excision (eliminating the abnormal tissue from the cornea and
sclera), MC works as an inhibitor of fibrovascular activity reducing its vascularity,
thereby decreasing the risk of recurrent pterygium.15
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Mitomycin C and DNA Adducts
MC is a very active anticancer and antibacterial agent because of its ability to
form MC-DNA adducts, but in order to modify the DNA, reduction steps are required.
For example, MC does not react with purified DNA in the absence of reducing enzymes
or added one or two electron chemical reductants.12,13 Evidence indicates that damage to
DNA in the tumor cell is generated by mono and bi-functional alkylation of guanine
residues by MC, leading to MC-guanine monoadducts 3 and MC-guanine bisadducts; the
latter include the DNA interstrand and intrastrand crosslinks 4 and 5 (Figure 1.2).16
DNA monoalkylation and crosslinking by MC is very selective for particular
DNA sequences. Monoalkylation occurs at 5'-CG-3' sequences approximately five times
over other 5'-NG-3' sequences (C= cytosine, G= guanine, N= any base). The covalent
bond is formed between MC and the 2-exocyclic amine group on guanine bases,
indicating that the DNA adduct is formed in the minor groove of the DNA duplex. While
monoalkylation of DNA exhibits a preference for 5'-CG-3' sequences, crosslinking occurs
exclusively at this sequence, as demonstrated by the fully characterized crosslinked DNA
adduct 4 that was isolated after enzymatic digestion.17,18 The solution structures of intact
DNA duplexes, either monoalkylated or crosslinked by MC, have been solved by the
NMR-molecular mechanics method that-include NOE intensity-based refinement. In the
case of a crosslinked DNA duplex, the MC residue fits inside the minor groove causing
little perturbation of the DNA backbone.19
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Figure 1.2

Structures of DNA adducts resulting from MC treatment.

The solution structure of the monoadduct indicates a specific alignment of the MC
residue in the minor groove of the DNA duplex.20 The conformation is supported by a
hydrogen bond between the oxygen atom at the C-10 of MC and the exocyclic amino
group of a guanine base on the strand complementary to the alkylated DNA strand
(Figure 1.3). Formation of an analogous hydrogen-bonded pre-covalent complex of an
activated form of MC has been suggested to explain the remarkable sequence recognition
in the alkylation process.21
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Figure 1.3
Monoalkylated MC-DNA adduct with proposed hydrogen bonding.
The monoalkylated [MC] dG adduct involves a covalent bond between C-1 and an amino
group on guanine and an intermolecular hydrogen bond between the ester oxygen
attached to C-10 and the amino group of another guanine base (G= guanine, C=
cytosine).
Proposed Mechanism of DNA Alkylation: Path 1 to ICLs
MC has many reactive groups, including the aziridine ring, the redox active
quinone, the carbamate at C-10, and the tertiary methoxy group at C-9a. Typically,
aziridine rings are very reactive due to the intrinsic ring strain. However, the aziridine
ring in MC, in its natural oxidized form and in moderately alkaline conditions, was found
to be unreactive.22 In contrast, under mildly acidic conditions, aziridine ring-opening is
accompanied by subsequent loss of the methoxy group at C-9a.3,23 The lack of reactivity
at neutral pH may be related to the stability of the tertiary methoxy group at C-9a, due to
the partial withdrawal of electrons from N-4 into the quinone ring, as represented by the
resonance forms shown in Figure 1.4.

Figure 1.4
Resonance forms of MC in the natural oxidation state. Resonance from
B depicts partial withdrawal of electrons from N-4 into the quinone ring.
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Because of the previously described lack of reactivity, MC does not react with
purified DNA unless the reaction mixture is supplemented with some source of chemical
or enzymatic reductant.24 At least five different enzymes have been shown to catalyze the
bioreduction of MC in vitro. These enzymes may also be present in solid tumors,
including a series of novel mitochondrial reductases such as cytochrome P450
reductase.23
The first step in the proposed reductive activation mechanism involves the
enzymatic conversion of the quinone moiety in MC to the hydroquinone 6, as shown in
Figure 1.5. The reduced quinone ring loses the capacity to withdraw electrons from N-4,
which localizes them on this center. The regaining of electrons and increase in basicity of
N-4 starts the remaining chain of events illustrated in Figure 1.5.9 The lone electron pair
on N-4 is able to facilitate the departure of the angular methoxy group. This event
affords, after loss of a proton, the intermediate 8, which is termed a leucoaziridinomitosene. Compound 8, with the reactive indolic tetracyclic ring system, acts as
the central branch point for two different pathways, monofunctional activation that leads
to DNA monoadducts and bifunctional activation that produces the more cytotoxic DNA
crosslinks.
The leuco-aziridinomitosene 8 has two “benzylic" electrophile sites, the C-N bond
at C-1 and the C-O bond at C-10. Due to the strained aziridine ring, the C-1 site is more
reactive. Upon acid catalyzed ring-opening, the resulting carbocation at C-1 is stabilized
as a result of conjugation with the aromatic system on 9. The previously described
hydrogen bonding, depicted above in Figure 1.3, situates the cation such that it is readily
able to react with DNA to form the monoadduct. Slower expulsion of the carbamate
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leaving group at C-10 generates a conjugated iminium ion 9b that will react with DNA to
give the crosslink 10. Upon exposure to air, the reduced hydroquinone is oxidized to the
more stable quinone 11.17,18

Figure 1.5
Proposed Mechanism of DNA Alkylation: Path 1 to ICLs. Reduction of
MC and loss of methanol generates a leuco-aziridinomitosene that bis-alkylates DNA.17,18
Proposed Mechanism: Path 2 to Form DNA Monoadducts
The crosslinking of DNA by MC is the most effective way to kill cancer cells.
However, forming an ICL is only one example of how MC can bind to DNA. In fact,
monoalkylation of DNA is actually 10-20 times more predominant than the lethal DNA
crosslink.25 Furthermore, monoalkylated adducts block DNA polymerases from
synthesizing DNA producing moderate cytotoxicity.26
In vitro, reaction conditions have been shown to control the extent of alkylation.
At higher pH (>7.4), slow reduction or high concentration of MC forms DNA
monoadducts preferentially over DNA crosslinks.17,18,27 Under these conditions, path 2
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dominates, and the leuco-aziridinomitosene 8 is rapidly converted to AZM 12 (Figure
1.6). Structurally, 12 is similar to MC, but has eliminated methanol such that the aziridine
ring and the carbamate remain activated. As before, strain associated with the threemembered aziridine ring allows for acid-catalyzed ring opening and subsequent DNA
monoalkylation at C-1. Although AZM 12 retains the carbamate at C-10, which is the
functional group responsible for the second alkylation step leading to ICL formation with
MC, the electron deficient quinone ring prevents its departure due to the resonance
effects described earlier and shown in Figure 1.4. Further, enzymatic reduction of the
quinone ring, analogous to that required for MC activation, is disfavored due to
congestion once bound to DNA in the minor groove.19,21 Consequently, DNA binding
does not proceed beyond the monoalkylation step.

Figure 1.6
Proposed Mechanism of DNA Alkylation: Path 2 to DNA
Monoadducts. Oxidation of the leuco-aziridinomitosene generates an AZM that
monoalkylates DNA.
Patrick and coworkers were able to isolate degradation products of the parent
mitomycins, such as 12, and reported that they had similar reactivity to the parent
mitomycins under reductive conditions.28 However, they were more sensitive to acidcatalyzed degradation compared to the parent mitomycins, as demonstrated by a half-life
of 3 minutes in solution at pH 7.0.28 Additionally, purified 12 was shown to bind to DNA
in vitro and to form the monoadduct 13 without reductive activation, lending support to
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the role of path 2 that results in formation of only monoadducts.29 For crosslinking to
occur, carbamate departure via an SN1 mechanism is required. This reaction is only
favorable at the reduced hydroquinone oxidation state, since the electron rich ring system
stabilizes the iminium ion intermediate 9b (from Figure 1.5).23 For the AZM 12, an
analogous iminium ion is destabilized due to the presence of the strong electronwithdrawing quinone. To restate the proposed mechanistic details, the ring strain
associated with the aziridine ring render it susceptible to opening at either the
hydroquinone (i.e., 8) or indoloquinone (AZM 12) oxidation states. On the other hand,
only the reduced form affords a viable pathway for carbamate departure and ensuing
DNA crosslinking, which explains why AZMs typically only monoalkyate DNA under
non-reductive conditions.
Introduction to Aziridinomitosenes
The reaction mechanism of path 2 involves formation of the intermediate AZM
12, followed by monoalkylation of with DNA.17,18,27 Studies with radioactively labeled
MC showed that formation of monoadducts occurs 10-20 times more than formation of
the crosslink.25 The monoalkylation of DNA prevent DNA polymerases from
synthesizing DNA and has moderate cytotoxicity.26 Crosslinking is still more potent than
the monoadducts. It was found, for example, that an estimated one ICL per 20,000
nucleotide base pairs was sufficient to stop further cell replication.27
In 1964, Patrick and coworkers investigated the structure of the mitomycins and
found that during hydrogenation of N-methylmitomycin A (14) over a platinum catalyst
at atmospheric pressure in N,N-dimethylformamide (DMF) solution, one molar
equivalent of hydrogen was absorbed.28 When the resulting colorless solution was
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reoxidized with air, a new compound was obtained in up to 40% yield (Figure 1.7). This
new compound, named 7-methoxy-1,2-(N-methylaziridino)mitosene (15), was the first
AZM to be isolated. The name “mitosene” was used to reflect the formal elimination of
methanol from the “mitosane” of the mytomycin core. A bioassay of the new compound
in vitro showed that it was an active antibiotic with a broad spectrum of antibacterial
activity similar to the parent mitomycin. In mice, the compound was found to be active
by both oral and subcutaneous routes against infections.28

Figure 1.7
Formation of an AZM from an mitomycin. Hydrogenation of a
mitomycin over platinum catalyst at and reoxidation results in an aziridinomitosene.28
In 1987, Danishefsky and coworkers generated and characterized
aziridinomitosene 15 in 90% yield by reacting N-methylmitomycin A (14) with 0.1
equivalent of ascorbic acid in pyridine. Ascorbic acid acted as a one-electron reducing
agent to form the active intermediate (semiquinone radical or radical anion) 16 and 17
(Figure 1.8).30 With 15 in hand, they were able to prepare the highly reactive leucoaziridinomitosene 18 by hydrogenation over Pd/C.31,32
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Figure 1.8

Danishefsky’s synthesis of an AZM and leuco-aziridinomitosene.

Total Synthesis of Mitomycins and Aziridinomitosenes
There have been a variety of synthetic approaches to the mitomycin and
aziridinomitosene skeleton. The majority of the published routes are concerned with the
formation of the tricyclic pyrrolo[l,2-a]indole ring system. A few research groups have
successfully introduced the carbamate at C-9 and achieved the correct quinone
substitution pattern.33 However, the mitomycins themselves were not synthesized until
Kishi and coworkers reported their syntheses of mitomycins A, C, and porfiromycin in
1977. 34 The lack of reported syntheses may be due to difficulties encountered during the
introduction of the angular C-9a methoxy group, since this is arguably the most labile
functionality present in the mitomycins.34,35
A number of aziridinomitosenes have been prepared by reduction of natural
mitomycins, followed by reoxidation of the intermediate hydroquinone.28,30 However, no
total synthesis of an aziridinomitosene at the correct oxidation state was reported until
1999, when Jimenez and Dong published their racemic synthesis.36 The preparation of the
fully functionalized aziridinomitosene was accomplished in 16 steps (3.4% overall yield)
from 2,5-dimethylanisole. Although the Jimenez/Dong sequence will be discussed in
detail in the next chapter, it is worth noting that their route is not amenable to the
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formation of single enantiomeric product since the aziridine ring was formed at late stage
from an achiral intermediate.
Vedejs and coworkers developed an enantiocontrolled route towards AZM 19
from nonaromatic precursors (Figure 1.19).37 The Vedejs approach was designed to allow
greater potential for variation of substituents at C-6 and C7 than is possible from the
natural products. However, the Vedejs aziridinomtiosene 19 lacks substituents at C-6 and
C-7, and therefore has additional electrophilic sites compared to the parent mitomycin.
The aziridinomitosene 19 and the C-6 methyl analog 20 relied on an azomethine ylide
cycloaddition sequence to construct the tetracyclic core. Overall, the two compounds
were prepared in 2.9% overall yield, in a longest linear sequence of 20 steps starting from
L-serine methyl ester hydrochloride.38 The Vedejs work is directly relevant to the
synthesis of the aziridinomitosene described in the next chapter.

Figure 1.9

Structures of AZMs synthesized and studied by Vedejs.

The Solvolytic Stability of Synthetic Aziridinomitosenes
The solvolytic stability of AZM 19 and other analogues were evaluated in
methanolic solutions buffered with the Tris and Bis-Tris amine hydrochlorides (Figure
1.10).38 The process was monitored by UV spectroscopy and compared with results
obtained by Kohn and Han for the methanolysis of AZM 21 under similar conditions.39
At pH 7.0, the results showed that methanolysis of AZM 19 is 160 times slower than 21.
Electron donation from the amino group on C-7 of 21 into the quinone π-system may
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explain the increased reactivity. The C-7 amine presumably provides additional
stabilization of the carbocation 25 that is formed upon SN1 aziridine ring-opening.
Carbocation 24 lacks a comparable electron-donating group, which affords
aziridinomitosene 19 increased stability under acidic conditions, compared to 21.
Under basic conditions, 21 was more stable than 19. In fact, 19 rapidly
decomposes to unidentifiable products in methanolic solutions buffered at pH 8.5. It
appears that the lack of functionalization at C-6 and C-7 enables nucleophilic attack at
one or both of these sites, initiating a process that leads to decomposition. AZM 21 has a
methyl at C-6 and an amine at C-7, rendering these sites unreactive to nucleophiles. The
methanolysis of 19 was also conducted under acidic conditions, at pH 5.8, and the ringopened 26 was obtained in 41% yield as a 1:1.2 mixture of the cis/trans isomers.

Figure 1.10

Methanolysis of the aziridinomitosenes 19 and 21.

Reactivity and Cytotoxicity of Synthetic Aziridinomitosenes
ICLs are the primary adducts formation that stop cancer cells from further
replication.40,41 AZM-DNA crosslinking experiments have been evaluated in vitro, and
the adducts characterized. The results showed that under hypoxic conditions in the
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presence of reducing agents, DNA crosslinking of the AZM and the parent mitomycin are
consistent and both are selective to 5'-d(CG) sequences.42,43
The ability of the synthetic AZM 19 to modify DNA was evaluated under
nonreductive conditions using the BstNI-EcoRI 129-bp fragment from pBR322 plasmid
that was 3' end-labeled with 32P.38 The site of DNA modification was determined using
the UvrABC nuclease assay, and it was found that AZM 19 modified DNA at guanine
residues. Also, increased incubation times gave a greater percentage of DNA adducts.38
The ability of AZM 19 to crosslink specific DNA sequences under aerobic,
nonreductive reaction conditions was tested and reported by using self-complimentary
14-base pair sequences.44 The results confirmed that AZM 19 produced AZM-DNA
interstrand crosslinks only in duplex DNA having the sequence 5'-d(CG). Also, no ICL
formation was observed with the inverted 5'-d(GC) dinucleotide sequence. The reaction
between DNA and AZM 19 was found to be pH-dependent, with the highest yield of ICL
observed at pH∼6.1, which indicates that moderate acid catalysis enhances DNA
modification. This data was the first evidence of sequence-specific DNA interstrand
crosslinking by an aziridinomitosene without prior activation by a reducing agent.
Warner and coworkers reported that the synthetic AZMs 19 and 20 were able to
form DNA crosslinks and DNA-protein adducts (DPCs) in Jurkat and HeLa cancer cells
after one hour of treatment in an aerobic environment.45 Cytotoxicity assays showed that
20 was up to 72 and 520 times more potent than MC and 19, respectively, against a
variety of adherent and non-adherent cancer cell lines. The IC₅₀ values for MC and 19
were typically in the low micromolar range, and in the sub-micromolar range for 20.
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The greater potency of 20 over MC may be due to a variety of chemical features.
First, the presence of the methyl group at C-6 will render 20 less susceptible than 19 to
Michael addition to the quinone ring, which should result in prolonged half-life within
the cell. Second, lack of a hydrophilic amine group at C-7 should allow for more facile
diffusion into cell. Third, the presence of the methyl group on the aziridine ring adds
additional stability in slightly acidic and neutral environments. All three of these factors
may improve the electrophilic integrity of the Me-AZM 20 and stabilize the molecule for
productive reactions with cellular nucleophiles. Finally, AZM 19 is more reactive under
basic/nucleophilic conditions and this may account for its decreased potency. This is
because the two electrophiles on C-6 and C-7 are very reactive to nucleophilic addition
that will give 19 a shorter half-life comparing with 20.45
While the mechanism of ICL and DPC formation by 19 and 20 is not completely
understood, Warner and coworkers have proposed two potential mechanisms involving
either acidic (Path A) or nucleophilic (Path B) activation that result in the formation of
crosslinks and/or DNA-protein adducts in tumor cells and in purified DNA. As shown in
Figure 1.11, Path A involves acidic ring-opening of the aziridine ring to produce a
relatively stable benzylic carbocation that is captured by nucleophilic DNA in the minor
groove to form monoadduct 29. Next, a slow, acid catalyzed carbamate cleavage
sequence forms an iminium intermediate that undergoes a second nucleophilic addition
that forms the ICL 31. Path A is consistent with the observation that 19 or 20 gives an
optimum yield of DNA ICLs in moderately acidic conditions (pH 6).44 Also, the methyl
group at the C-6 carbon on 20 is a mild electron donor that provides additional
stabilization to the cations formed upon aziridine ring-opening and carbamate departure.
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This enhanced stability may account for the increased activity of 20, compared to 19,
against the cancer cell lines tested.

Figure 1.11 Proposed mechanism of AZM ICL formation: Path A. Acidic
activation of 20 results in aziridine ring-opening and carbamate departure to form an ICL.
The proposed mechanism that invokes a nucleophilic activation sequence (Path B,
Figure 1.12) also relies upon acid catalyzed aziridine ring-opening to form the DNAmonoadduct 29 as the first step. Next, nucleophilic addition to C-7 by a DNA-associated
protein or other cellular nucleophile will result in an intermediate 32 that can tautomerize
to the hydroquinone species 33. This intermediate is analogous to the previously
described leuco-aziridinomitosene, from Figure 1.5, that has sufficient electron density to
allow carbamate departure and crosslink formation. Compared to the acidic activation
sequence, the nucleophilic mechanism has the advantage of explaining the formation of
DNA-protein adducts. Additionally, this mechanism offers an explanation as to why 19
isn’t as active against cancer cells as 20. On aziridinomitosene 19, there are two sites for
nucleophilic addition (C-6 and C-7), whereas 20 has only one site (C-6). Consequently,
19 is more accessible to nucleophilic attack that occurs prior to DNA alkylation, which
results in aziridinomitosene decomposition before cell-killing events. The methyl group

17
at C-6 on 20 prevents nucleophilic attack at that carbon and offers moderate steric
hindrance that slows attack at C-7. Together, these things are proposed to allow 20 to
alkylate DNA with minimal prior decomposition.45

Figure 1.12 Proposed mechanism of AZM ICL formation: Path B. Nucleophilic
addition, by a protein or cellular nucleophile, activates the quinone ring for carbamate
departure and ICL or DPC formation.
To test the validity of the two proposed mechanisms, a new AZM, compound 35,
that has methyl groups at both C-6 and C-7 needs to be constructed. If the acidic
activation sequence predominates, then the new aziridinomitosene 35 is expected to form
DNA crosslinks to a greater extent than both compounds 19 and 20. If the nucleophilic
mechanism is most important, then the new compound would not exhibit crosslinking to
any extent since both C-6 and C-7 would no longer be available to cellular and other
nucleophiles. Also, we expect that in acidic conditions the aziridine ring on 35 should
open faster than 19 and 20 since the methyl groups on C-6 and C-7 will stabilize the
carbocation on C-1. In basic/nucleophilic conditions, we expect that 35 will be more
stable than 19 and 20 because the methyl groups at C-6 and C-7 will prevent nucleophilic
attack, which will prevent formation of 33. Thus, the focus of this thesis project is to
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complete the synthesis of aziridinomitosene 35 and to conduct preliminary experiments
to explore its reactivity. Results of these efforts are described in the next chapter.

Figure 1.13

The C-6/C-7 dimethyl AZM 35, designed to test the nucleophilic
addition mechanism.
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CHAPTER TWO: TOTAL SYNTHESIS OF A 6,7-DIMETHYL-N-METHYL
AZIRIDINOMITOSENE
Introduction
Recent efforts in the Warner laboratory have focused on the biological evaluation
of synthetic aziridinomitosenes (AZMs) that are structurally related to MC. Two of these,
AZMs 1 and 2 (Figure 2-1) were evaluated for their cytotoxic activity against cancer
cells, and tested for their DNA-modifying abilities in Jurkat cells.1 The study showed that
2 is at least 2.75 and 5.5 fold more potent than MC and 1, respectively; and is up to 72
and 520 times more potent, against a variety of cancer cell lines. Also, evidence for the
formation of interstrand crosslinks (ICLs) and DNA-protein crosslinks (DPCs) in cellular
systems was obtained using a modified alkaline single cell gel electrophoresis (COMET)
assay and a K-SDS DNA-protein crosslinking assay. These results support that
modification of DNA by AZMs 1 and 2 is a potential mechanism of their cytotoxicity.

Figure 2.1
Structures of Synthetic AZMs and MC. AZM 1 is unsubstituted at C-6
and C-7, while 2 has a methyl group at C-6. AZM 3 is the focus of this thesis project.
Two potential mechanisms were proposed to explain the formation of ICLs and
DPCs in reactions with DNA, one involving acidic activation and the other nucleophilic
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activation. The nucleophilic mechanism, which is most consistent with the observed data,
invokes addition of a nucleophile at the unsubstituted C-6 or C-7 sites as the key step
leading to ICLs and DPCs. To test the validity of this hypothesis, the focus of the
research described herein involves the synthesis of the new AZM 3 (Figure 2.1) where
both sites are blocked to prevent nucleophilic attack. AZM 3 retains the reactive aziridine
ring at C-1 and carbamate at C-10, as well as the indoloquinone group present in other
AZMs. The new AZM is hypothesized to either reduce the extent of ICL and DPC
formation, or prevent them from forming in the first place, under non-reductive
conditions. This chapter first presents prior syntheses of AZMs in order to place this
work in context, and then describes the synthesis of AZM 3, along with preliminary
results investigating the new compound’s activity in methanolic buffered solutions at
different pH values.
Previous Syntheses of Aziridinomitosenes
Since the isolation of mitomycins and AZMs over 60 years ago,2,3 much attention
has been devoted to the study and synthesis of these compounds, primarily due to their
unique tetracyclic structure and high cytotoxicity. The total syntheses of mitomycin A, C,
and porfiromycin was achieved in 1977 by Fukuyama and Kishi.4 While there have been
many attempts at the total synthesis of AZMs, very few researchers have succeeded. In
1985, Rapoport and coworkers reported an asymmetric synthesis of the AZM-type
compound 4 (Figure 2.2).5 Notably, the reduction of the carbonyl at C-10 was
problematic, which prohibited installation of the essential carbamate group. Also,
removal of the benzyl protecting group from the nitrogen of the strained aziridine ring
could not be accomplished.
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To understand the mode of action for MC and related agents, Edstrom and coworkers reported their synthesis of analog 6 (Figure 2.2).6 The synthesis involved the
conversion of tricyclic compound 5 to the final tetracyclic product 6. The compound
contains the indoloquinone, an N-H aziridine ring, a methyl group at C-6, and the
appropriate amine functionalization at C-7. However, Edstrom’s final product contained
an ester moiety at C-10, the same group that was problematic in Rapoport’s synthesis. As
before, the carboxyl could not be reduced and Edstrom’s final compound lacked the
reactive carbamate required for DNA ICL formation.

Figure 2.2

AZMs prepared by Rapoport and Edstrom. In both methods, the
reduction of the carbonyl at C-10 was problematic.

The total synthesis of a fully functionalized aziridinomitosene, at the correct
oxidation state at all carbons, continued to be unsuccessful until 1999 when Jimenez and
Dong report their racemic synthesis of AZM 20 (Figure 2.3).7 The Jimenez AZM is fully
functionalized, including the N-H aziridine ring and the carbamate functional group at C10. Starting from 2,5-dimethyl anisole, the synthesis required 16 steps and produced the
final product in 3.4% overall yield.
In the first step, 2,5-dimethylanisole was nitrated on a 50 g scale with sodium
nitrite in trifluoroacetic acid to prepare 7 (Figure 2.3). The α-keto ester 8 was prepared in
a 63% yield from 7, using dimethyl oxalate and potassium tert-butoxide. Reaction of 8
with 3 equivalents of stannous chloride in methanol resulted in a 60% yield of the
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Figure 2.3
The Jimenez and Dong racemic synthesis of an AZM. The first
synthesis of an AZM (20) required 16 steps from 2,5-dimethylanisole and gave the final
product in 3.4% overall yield.
hydroxyindole 9, and subsequent hydrogenation over Pd/C in methanol gave a
quantitative yield of 10. Potassium nitrosodisulfonate (Fremy’s salt) was used to oxidize
indole 10 to the corresponding quinone 11. This compound was used in the next reaction
without further purification to give the protected hydroquinone 12, which was formed by
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catalytic hydrogenation of 11, followed by treatment with 4 equivalents of tertbutyldimethylsilyl chloride and imidazole. Reduction of 12 with DIBAL gave a primary
alcohol that was converted to the corresponding aldehyde 13 with MnO2 in 85% yield.
In the key step that forms the third ring and sets the stage for aziridine formation,
indole 13 is treated with diisopropylvinylsulfonium triflate in the presence of sodium
hydride to give the intermediate 14b. The resulting tetracyclic epoxide was treated with
sodium azide to form a racemic azido alcohol that is then mesylated to give compound
15. The aldehyde 16 was obtained from 15 by Vilsmeier-Haack formylation in 96%
yield, followed by formation of the quinone ring by oxidative cleavage of the TBS groups
with PCC in 81% yield over the two steps. Alcohol 17 was obtained in 74% yield after
the aldehyde was reduced with NaBH4 in methanol. The quinone ring, which had been
reduced in the NaBH4 step, was reoxidized with molecular oxygen. The carbamate 19
was obtained in 77% by treating alcohol 17 with phenyl chloroformate and then
ammonia. Lastly, the aziridine ring was formed by reduction of the azide with
triphenylphosphine and ensuing ring-closure and mesylate departure to give AZM 20 in
70% yield. The synthesis is noteworthy in that it was the first to accomplish the synthesis
of a fully functionalized AZM. However, the key step that allows for installation of the
aziridine ring was racemic. Thus, an enantiocontrolled route to a functionalized AZM still
remains elusive.
Enantiocontrolled Synthesis of Aziridinomitosenes
Relevant to the thesis work described herein, Vedejs and coworkers developed an
enantiocontrolled route towards aziridinomitosenes that uses an azomethine ylide
cycloaddition approach to construct the tetracyclic core (Figure 2-4).8,9 The synthesis
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began by preparation of oxazole 22, which was formed via treatment of methyl ester 21a
or lactone 21b with lithiated methyl isocyanide using the Schöllkopf oxazole synthesis.
Oxazole 22 was treated with borane, then n-butyllithium to give the lithiated borane
complex 23. The resulting intermediate was coupled with a serine-derived aldehyde, to
give amino alcohol 24 as an inseparable 6:1 diastereomeric mixture, in 93% yield.

Figure 2.4.

Vedejs synthesis of oxazole 22 and amino alcohol 24.

Treatment of 24 with diethyl azodicarboxylate and triphenylphosphine under
Mitsunobu conditions closed the aziridine ring and allowed separation of the
diastereomeric mixture (Figure 2.5). The desired cis-fused ring 25 was obtained in 71%
yield and 98.1% enantiomeric excess. Intermediate 25 was converted to cycloaddition
precursor 26 over 7 steps and in 26% yield.

Figure 2.5

Vedejs synthesis of tetracyclic precursor.

The tetracyclic compound 27 was prepared in 37% yield by the internal
azomethine ylide cycloaddition sequence shown in Figure 2.6. First, the oxazolium salt
28a was formed by intramolecular N-alkylation upon treatment of precursor 27 with
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AgOTf. Addition of 28a to a solution of BnMe₃N⁺CN⁻ afforded 4-oxazoline 28b, which
spontaneously ring opens to the azomethine ylide 28c. The reactive azomethine ylide
undergoes a [3+2] cycloaddition to give 28d, which, upon HCN elimination, aromatizes
to form tetracycle 29.

Figure 2.6

Mechanism of the oxazolium salt/azomethine ylide cycloaddition.

The desired aziridinomitosene 2 was formed after 6 steps that included removing
the acetate group, oxidation to the quinone, and, finally, attaching the carbamate group
(Figure 2.7). The C-6 methyl AZM 2 was isolated in an overall yield of 0.03% from Lserine methyl ester hydrochloride. An analogous route was used to prepare the
corresponding C6/C7 unsubstituted AZM 1, which was obtained in 2.9% overall yield.

Figure 2.7

Formation of aziridinomitosene 2.
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Results and Discussion
The Vedejs route previously used to prepare the C-6/C-7 unsubstituted and C-6
methyl substituted aziridinomitosenes was envisioned to provide access to the C-6/C-7
dimethyl substituted analog that is the target of this work (i.e., compound 3). As a result,
the first problem that needed to be solved was the synthesis of either an ester or lactone
that would serve as an entry into the complete synthesis. The simplest protocol involved a
four-step sequence that converted 1,2-propanediol to the ester 34, subsequent oxazole
formation, and then formation of the oxazolium salt cycloaddition precursor (Figure 2.8).
The only drawback to this approach stems from the lack of stereocontrol, since several
reactions would require purification of mixtures that contained up to 8 different
stereoisomers. However, this potential problem was deemed acceptable given that all of
the epimeric centers are erased during the synthesis and the final product would be
produced as a single enantiomer.
To begin, the primary alcohol of commercially available 1,2-propanediol (30) was
selectively protected using tert-butyldimethylsilyl chloride and catalytic
dimethylaminopyridine (DMAP).10,11 Presumably, the increased steric hindrance of the
secondary alcohol directs the silane to the primary alcohol and the desired product 31 was
generated in sufficient purity to be used in the next step without any purification. The
resulting secondary alcohol was oxidized via PCC to give ketone 32.12,13 The overall
yield for the two step sequence was 41.4%, with most of the material lost due to
difficulties extracting the product from the chromium waste generated during the PCC
reaction. As a result, a Dess-Martin periodinane oxidation was also attempted, but it did
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not result in any improvements, possibly due to the adjacent sterically hindered silyl ether
slowing the reaction rate.14

Figure 2.8

Synthesis of oxazole intermediate 35. The compound 35 was prepared in
15% yield over 5 steps from the starting diol.

Next, a Horner-Wadsworth-Emmons reaction with commercially available
triethyl 2-phosphonopropionate was used to convert the ketone into the unsaturated ester
33.15 Owing to the product being a somewhat sterically hindered tetra-substituted olefin,
the reaction required stirring for 24 hours to consume all starting material. However, the
product could be obtained in good yield (76%), as an inseparable mixture of E and Z
isomers in approximately a 1:1 ratio. Conjugate reduction of the enoate 33 was
accomplished using H2 and Pd/C to give the saturated ester 34 in 95% yield.16 On paper,
this reduction seems quite trivial. In practice, however, it proved a bit troublesome. For
example, if the precursor 31 was oxidized using a Swern oxidation, the reduction failed.
This was the outcome even if the product was purified via distillation or via silica gel
chromatography, and even though the alcohol to ketone oxidation step was conducted
several steps prior to reduction of 33. It is surmised that residual dimethyl sulfide, a byproduct of Swern oxidation, poisoned the palladium catalyst and prevented reduction.
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When the oxidation of alcohol 31 was conducted with PCC, alkene reduction occurred
without any difficulty.
To prepare oxazole 35, ester 34 was treated with lithiated methyl isocyanide, in
what is termed a Schöllkopf oxazole synthesis.17 To conduct this reaction, methyl
isocyanide (MeNC) is first prepared by dehydrating N-methyl formamide with
toluenesulfonyl chloride (TsCl),18 distilling the foul-smelling isocyanide, deprotonating
with nBuLi at -78 °C, and then adding 34 dropwise. The most notable aspect of this
reaction is that care must be taken to minimize exposure to the noxious odors that result
from the MeNC, complicating the purification steps. Ultimately, oxazole 35 is formed in
50% yield after purification by column chromatography and then vacuum distillation. A
total of 6.83 g of the oxazole was formed, which corresponds to an overall yield of 14.9%
for the 5 steps from the diol.
Alkylation of oxazole 35 to yield amino alcohol 39 was accomplished over
several steps by treating the lithiated oxazole with a serine-derived aldehyde (Figure 2.9).
First, the oxazole-borane complex 36 was formed to prevent electrocyclic ring-opening
after adding n-BuLi,19 and this allowed alkylation at C-2 specifically without competing
alkylation at C-4. Second, adding n-BuLi to the prepared complex gave 37, which then
underwent nucleophilic addition reaction to the aldehyde 38. The amino alcohol 39 was
obtained in 80% yield as a mixture of six inseparable diastereomers, in a 6:6:6:1:1:1 ratio.
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Figure 2.9

Nucleophile addition to aldehyde 38. The amino alcohol 39 is formed in
80% yield as a mixture of six diastereomers in a 6:6:6:1:1:1 ratio.

Although the reaction sequence shown in Figure 2.9 was eventually successful,
the nucleophilic addition of the oxazole to the aldehyde reaction required significant
optimization in order to provide 39 in an acceptable yield. In order to identify problems
with the reaction, the ability to form intermediate 37 was tested by duplicating the
reaction under similar conditions, but instead of adding the aldehyde 38 to form the
amino alcohol 39, the intermediate was quenched by deuterated methanol to yield 35b
(Figure 2.10). According to NMR assay, 80% of 35 was converted to 35b.This result
confirmed that while 36 and 37 were formed, the intermediate 37 was not reacting with
the more hindered aldehyde at the reaction temperature (-78 °C) or during the allotted
time (originally 1 hour at -78 °C). To remedy this problem, the stirring time was
increased as was the reaction temperature. Eventually, after conducting the reaction 12
different times, it was found that the optimum conditions involved first stirring 37 with
the aldehyde 38 for 2 hours at -78 °C, slowly warming the reaction to 0 oC over 2 hours,
and then stopping the reaction. This protocol reliably provided the desired product in at
least 80% yield.
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Figure 2.10

Formation of the deutoro-oxazole to confirm the formation of the
intermediate 37.

The stereochemistry of the amino alcohol and, ultimately, the absolute
configuration of the final aziridinomitosene product relies upon the aldehyde 38, which
was prepared from the commercially available N-trityl-L-serine methyl ester (Figure
2.11). To produce the aldehyde, the primary alcohol was protected as an allyl ether and
then the ester was reduced to the corresponding aldehyde in high yield using DIBAL at 78 °C following a published protocol.9

Figure 2.11

Synthesis of aldehyde 38 from N-Trityl-L-serine methyl ester.

With the amino alcohol 39 now available, the aziridine ring was closed using
Mitsunobu conditions, affording the aziridine 40 in 86% yield as a single epimer at the
aziridine ring after purification, indicating that the trans aziridine by-product could be
removed via silica gel chromatography (Figure 2.12).20 Next, removal of the trityl
protecting group was achieved using ionic reduction conditions. Specifically, 40 was
treated with triethylsilane and trifluoroacetic to provide 41 in 84% yield.8 The N-methyl
aziridine was generated by deprotonation of the N-H aziridine at -78 °C using n-BuLi,
and the resulting anion was treated with methyl iodide to provide the desired product 42
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in 83% yield. Removal of the allyl protecting group from 42, achieved using an in situ
generated zirconium (II) reagent, provided the desired alcohol 43 in 83% yield.21

Figure 2.12 Synthesis of the cycloaddition precursor 48 in 2.8% overall yield. The
sequence required 15 steps from 1,3-propanediol and 10 steps from oxazole 39 (and 19%
overall yield).
The next step in the synthesis involved converting the just produced alcohol to a
corresponding primary iodide in order to achieve the intramolecular oxazolium salt
formation. To accomplish this, Mitsunobu conditions were applied to form iodide 44 in
87% yield.22 Remarkably, even though the primary iodide is situated between two
neighboring nucleophiles, the aziridine and oxazole nitrogen atoms, it displays
remarkable stability over the remaining reaction steps, most likely due to steric protection
from the cis-fused aziridine ring.
The remaining steps required to synthesize the cycloaddition precursor involved
removing the tert-butyldimethylsilyl protecting group from 44 to yield the alcohol 45 in
90% yield by using the HF-pyridine reagent.23 The Dess-Martin reagent was used to
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oxidize alcohol 45 to generate the aldehyde 46 in 78% yield.14 Of the potential mild
oxidizing agents that could afford the same product, the Dess-Martin reagent was chosen
since the product could be obtained in pure form after a simple extraction step and
without silica gel chromatography. Addition of aldehyde 46 to lithiated tertbutyldimethylsilyl propargyl ether at -40 °C generated the alcohol 47 in 93% yield, which
was subsequently treated with acetic anhydride to afford the fully protected cycloaddition
precursor 48 in 84% yield as an inseparable 1:1:1:1 mixture of four diastereomers (Figure
2-12). The sequence to prepare the cycloaddition precursor 48 from the oxazole 39
required 10 steps and produced the compound in 19% yield. Overall, the synthesis of 48
was accomplished in 2.8% overall yield in 15 steps from commercially available 1,2propanediol.
The next step in the synthesis relies on the Vedejs oxazolium salt/azomethine
ylide cycloaddition sequence to form the tetracycle present in the final product.9 The
reaction proceeds following the mechanism shown in Figure 2.13. First, silver triflate
(AgOTf) is added to the primary iodide 48, and the strong affinity for silver towards
halides assists in formation of the oxazolium salt via an intramolecular SN2 reaction,
although the reaction still requires heating at 70 °C in acetonitrile for 3 hours for
complete consumption of the starting iodide. Next, the dark brown solution is transferred
dropwise via cannula to a flask containing a solution of BnMe3N+CN- in acetonitrile to
initiate the cycloaddition sequence. Specifically, cyanide adds to C-2 of the oxazolium
salt to give the 4-oxazoline 48b. This intermediate spontaneously ring opens to form the
azomethine ylide 48c, which undergoes an intermolecular [3+2]-cycloaddition to give the
3-pyrroline 48d. Lastly, elimination of proton and cyanide group aromatizes the five-
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membered ring and gives the product 49.8,9 Interestingly, a bright yellow color appears
and quickly dissipates after each drop. This yellow color is tentatively attributed to the
transient azomethine ylide intermediate and offers tentative evidence that the reaction is
generating the desired product.

Figure 2.13

Oxazolium salt/azomethine ylide cycloaddition mechanism.

Unfortunately, the cycloaddition reaction typically gave product in about a 30%
yield. While this low yield is not too disappointing considering the complexity of the
reaction to form the tetracyclic core, generating enough material to complete the
synthesis became somewhat problematic. As a result, the reaction was subjected to
additional investigation in order to increase the yield. To choose better conditions, we
decided to monitor the formation of the oxazolium salt by 1H NMR. The reaction began
by heating a solution of iodide 48 in CD3CN with silver triflate at 70 °C in an NMR tube.
Over several hours, the color of the yellow solution began to change to light brown and a
yellow solid, corresponding to AgI, began to form. Progress of the reaction was checked
every hour, and the results showed increasing formation of 48a each hour, where the peak
corresponding to the aromatic proton on C-4 (δ=6.89 ppm) started to disappear, and a
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new, downfield peak (δ=7.46 ppm) began to appear. The new peak is attributed to the
aromatic proton at C-4 on the oxazolium salt that has been shifted downfield due to the
deshielding effects of the positively charged oxazolium salt (figure 5-14). After seven
hours, the decision was made to stop the reaction as new peaks started to appear, which
indicated that decomposition may have occurred. The highest yield obtained from the
cycloaddition reaction was 44%, after modifying the conditions of the oxazolium salt
forming step to stir while heating for 6 hours instead of 3 hours. After silica gel
purification, the product was more than 90% pure, since achieving 100% purity was
difficult because tetracycle 49 is moderately unstable and decomposes during the
purification process.

Figure 2.14 Oxazolium salt formation process monitored by 1H NMR. The peaks
under the blue star, corresponding to the aromatic proton on C-4 (δ=6.89 ppm), started to
disappear over the time. The peaks under the red star, corresponding to a new peak at
δ=7.46 ppm, began to appear and increase over the reaction time.
After the cycloaddition sequence, the remaining steps involve formation of the
quinone ring and installation of the carbamate leaving group. The first step in the process
to form the quinone ring involves removal of the acetate protecting group from 49 to
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provide the corresponding secondary alcohol 50 (Figure 2-15), which was very sensitive
to decomposition on silica gel. Since even a fast filtration of the reaction mixture resulted
in loss of product, it was decided that it was better to go to the next step without
purification. Next, a non-acidic oxidation was needed to convert 50 to diketone 51, and
this was accomplished using the mildly basic tetrapropylammonium perruthenate/Nmethyl morpholine N-oxide (TPAP/NMO) in the presence of molecular sieves. The
diketone 51 was produced in 48% yield over two steps from the acetate 49.24

Figure 2.15

Formation of diketone 51 in two steps and 48% yield.

Quinone 52 was formed by treating diketone 51 with diazabicyclo[2.2.2]octane
(DABCO) as a base in acetonitrile under an oxygen atmosphere with a catalytic additive
of N,N′-bis(salicylidene)ethylenediaminocobalt(II) complex (Figure 2.16).25 The
purification of the quinone by silica gel column chromatography was difficult since the
starting diketone and the quinone product have similar polarities and tend to co-elute. A
better method involved preparative thin layer silica gel chromatography, but this method
caused some of the product to decompose since the products are in contact with the
mildly acidic silica gel for a greater amount of time. Ultimately, the quinone was
obtained in 35% yield, which allowed for the next deprotection step to be conducted. The
highly sensitive quinone, carefully treated with HF-pyridine buffered with
trimethylamine, generated alcohol 53 in 60% yield and with 28% recovery of the starting
quinone.
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Figure 2.16

Final four steps to produce C-6/C-7 dimethyl AZM 3.

The last step in the synthesis required attaching the carbamate group. Previous
experience with other AZMs relied on a one-pot procedure that involved first installing
an Fmoc-protected carbamate and then subsequent removal of the protecting group to
give the final product. However, in this instance, the one-pot reaction did not achieve the
desired product. As a result, the final product was prepared using a 2-step sequence
where the Fmoc-protected AZM 54 was isolated and purified in 50% yield, and then a
second deprotection step gave the final product 3 in 70% yield.8,9,26 The AZM was
characterized by 1H NMR, 13C NMR, and high resolution mass spectrometry. In
summary, the oxazole 35 was produced in 15% yield over 5 steps, the cycloaddition
precursor in 2.8% yield over 15 steps, and the final product in 0.04% yield from the
starting diol. In general, the synthesis of all intermediates up to the cycloaddition
precursor 48 proceeded without too much difficulty. However, all of the reactions postcycloaddition were more troublesome than has been observed for other
aziridinomitosenes. It appears that compounds 49 to 54 and the final product 3 are all
more sensitive than the comparable intermediates in other systems. As is discussed

40
below, AZM 3 appears to be more susceptible to acid-catalyzed decomposition pathways
and this may be the cause of the reduced yields.
The Solvolytic Stability of a 6,7-Dimethyl Aziridinomitosene
The solvolytic stability of 3 was evaluated in methanolic solution buffered with
the Tris and Bis-Tris amine hydrochlorides and the results were compared to those
obtained for previously studied aziridinomitosenes (Figure 2.17).27,28 UV spectroscopy
was used to monitor the solvolysis process in acidic, neutral, and basic buffer solution
(pH 6, pH 7, pH 8.7), respectively. The rate of solvolysis was measured by monitoring
the decrease in UV absorption at 480 nm over time. The results were fitted to the first
order rate equation to generate first order rate constants and half-lifes. Each solvolysis
experiment was repeated 2 times, and the mean values are reported in Table 2-1, as are
literature values for the previously known AZMs 1 and 55.
Table 2.1.

Methanolysis of Aziridinomitosene 1, 3, and 55, at 20 °C.
1

3

55

pH

k (s-1)

t1/2 (min)

k (s-1)

t1/2 (min)

k (s-1)

t1/2 (min)

6.0

3x10-5

400

15x10-5

74

-

-

7.0

5x10-6

2000

21x10-6

537

8x10-4

14

8.5

Decomp

Decomp

0

0

3.6x10-5

324

At pH 6, the new AZM 3 underwent methanolysis about five times faster than 1.
Under acidic pH, the AZMs undergo solvolysis by the sequence of events depicted in
Figure 2.17.9 Following protonation of the aziridine nitrogen, rapid ring-opening
generates a carbocation on C-1. Comparing the carbocations 1b and 3b, the electrondonating methyl groups at C-6 and C-7 on 3b provide additional stabilization, which
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results in faster SN1 ring-opening of the aziridine ring. A similar trend is observed at pH
7, where methanolysis of 3 was about 4 times faster than AZM 1. A comparison of 3 to
55 was permissible at pH 7, since the experimental results have been reported at this
pH.9,27,28 The synthetic AZM 3 underwent methanolysis about 38 times slower than 55. It
is reasonable to presume that the C-7 amino group present in 55 is a much better electron
donating group than the methyl group in 3. This will provide much greater stabilization
of the carbocation 55b, compared to 3b.

Figure 2.17

Methanolysis and azridine ring opening of AZMs 1, 3, and 55 in
buffered methanol solutions.

Under basic conditions, at pH 8.5, AZM 3 displays remarkable stability that is in
stark contrast to both AZM 1 and 55. Indeed, synthetic 3 did not undergo any detectible
change over 3000 minutes in methanolic solutions at pH 8.5. AZM 1 completely
decomposed after 10 hours, while 55 underwent aziridine ring-opening with a half-life of
228 minutes at this pH 8.5.28 The base catalyzed decomposition of 1 is postulated to
involve nucleophilic attack at the C-6 and C-7 positions on the quinone ring. Since

42
aziridinomitosene 3 is substituted with methyl groups at both of these positions, this
decomposition pathway is no longer available and offers an explanation for the
remarkable stability in basic solutions.
Conclusions
The total synthesis of AZM 3 started from commercially available reagents to
form the oxazole 35 in 5 steps (overall yield of 14.9%), followed by the addition of a
protected aldehyde that is converted to the required aziridine ring via a Mitsunobu
reaction. Once the aziridine ring is formed, all of the reaction conditions were performed
in mild conditions in order to prevent aziridine ring-opening. In an additional eight steps,
the cycladdition precursor 48 was formed in 19% yield from the prepared oxazole 35, and
in 2.8% overall yield from the starting diol. The completion of the synthesis and
formation of the tetracyclic core 49 was achieved by performing an oxazolium
salt/azomethine ylide, [3+2] cycloaddition sequence. This sequence was conducted
multiple times, and the highest yield obtained was 44%. The final steps were most
challenging, requiring several transformations to accomplish a deprotection and an
oxidation to give a diketone that was then further oxidized to a quinone. Finally, the
carbamate was attached in two steps using FmocNCO to yield the desired AZM 3 product
in an overall yield of 0.04% from the starting diol over the 22 step reaction sequence.
The solvolytic stability of 3 was evaluated in a methanolic solution buffered with
Tris and Bis-Tris amine hydrochlorides and compared to other AZM’s analogs. The
results of the study showed that under acidic conditions, at pH 6, AZM 3 was about five
times reactive than 1. The electron-donating methyl groups at C-6 and C-7 on AZM 3
provide additional stabilization to the carbocation that formed on the C-1, which results
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in faster SN1 ring-opening of the aziridine ring. A similar trend is observed at pH 7.
Under basic conditions (pH 8.5), AZM 3 is more stable than 1 and 55, and no aziridine
ring opening was observed over 50 hours. AZM 1 completely decomposed after 10 hours,
while 55 underwent aziridine ring-opening with a half-life of 5.4 Hours at this pH. The
presence of the methyl group on C-6 and C-7 in 3 was able to prevent any nucleophile
attack on the quinone moiety and did not undergo any change over 50 hours in
methanolic solutions at pH 8.5.
The results support that the nucleophile activation mechanism offers a viable path for 1
and 2 to form ICLs or DPCs. To explain the results, the aziridine ring in synthetic AZM 3
opens rapidly at pH 6 and pH 7, which is essential for the formation of DNA
monoadducts. AZM 3 was stable in more basic solutions, which suggests that nucleophile
attack on the quinone moiety is prevented due to the methyl groups at C-6 and C-7.
Nucleophilic addition to C-6 or C-7 in AZM 1 and to C-7 in AZM 2 by a DNAassociated protein or other cellular nucleophile will result in an intermediate that can
tautomerize to the hydroquinone species. This intermediate is analogous to the previously
described leuco-aziridinomitosene, from Figure 1.5, that has sufficient electron density to
allow carbamate departure and then crosslink formation. Future work will be directed to
determining the DNA crosslinking ability of AZM 3 and to improve the overall yield of
the final aziridinomitosenes.
Experimental
General Methods. Solvents and reagents were purified as follows: diethyl ether
and tetrahydrofuran (THF) were distilled from sodium/benzophenone; dichloromethane
(CH2Cl2) was distilled from P2O5; CH3CN was distilled from P2O5; DMF was stored over
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activated molecular sieves (3 Å, 4-8 mesh beads) for three days prior to distilling from
P2O5; benzene, toluene, triethylamine, NEtiPr2, and TMEDA were distilled from CaH2;
methanol was distilled from magnesium, the purified reagents and solvents were used
immediately or stored under nitrogen. NMR solvents (CDCl3, CD3CN) were stored over
activated molecular sieves (3 Å, 4-8 mesh beads). Molecular sieves (Aldrich, 3 Å, 4-8
mesh beads, or 4 Å, <5 micron powder) were activated at 200 °C and 0.5 mm Hg vacuum
for 24 h and stored under argon. Unless otherwise noted, all chemicals were used as
obtained from commercial sources and all reactions were performed under nitrogen
atmosphere in glassware dried in an oven (140 °C) and cooled with a stream of nitrogen.
All reaction mixtures were stirred magnetically and liquid reagents were dispensed with
all PP/PE plastic syringes or Hamilton Gastight microsyringes. Preparatory layer
chromatography (PLC) was performed using MN-Silica gel P/UV254 or Whatman PK6F
Silica gel 60 and analytical TLC was performed on EM glass plates coated with a 250 𝜇m
layer of silica gel 60 F254. Flash chromatography was performed with 230-400 mesh silica
gel 60.
4-(tert-Butyldimethylsilyloxy)-2,3-dimethyl-2-butenoic acid ethyl ester (33).
Sodium metal (2.560 g, 111.500 mmol) was added portion wise to 84 mL dry ethanol and
allowed to fully dissolve. (23.92 mL, 111.500 mmol) triethyl 2-phosphonopropionate was
then added dropwise and stirred for 20 minutes. (14.0 g, 74.333 mmol) ketone 32 was
dissolved in (30+20) mL ethanol and cannulated to the reaction mixture dropwise .The
resulting yellow solution was then stirred for 24 hours at room temperature . By the time
the color of the solution start to be orange. After 24 hour the consumption of the starting
ketone was checked by TLC eluted by (hexane 8:1 acetone), no starting materials was
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present. (84 mL) of saturated NH4Cl was added and then transferred to separation funnel
(150 mL) H2O was added and extracted with 3x200 mL DCM. The combined extracts
were dried (MgSO4), filtered and concentrated by rotary evaporation and the residue was
purified by flash chromatography on silica gel (25x18.5 cm, 20:1 hexane/ethyl acetate
eluent, 25 mL fractions). Fractions 18-50 gave 15.7g (76%) of the unsaturated ester 33 as
a colorless oil, analytical TLC on silica gel 60 F254, 20:1 hexane/ ethyl acetate, Rf= 0.2.
Molecular ion (M+H+) calcd for C14H29O3Si: 273.1880; found m/z= 273.1908, error=
10.249 ppm; IR (neat, cm-1) 1710.55, C=O, 1635.91, C=C; 600 MHz NMR (CDCl3,
ppm) δ 4.50 (1 H, s) 4.24 (1 H, s) 4.1 (2 H, dq, J=7.2, 5.9) 2.01 (1 H, s) 1.89 (2 H, s)
1.87-1.85 (3 H, s) 1.33-1.30 (3 H, m) 0.93 (3 H, s) 0.92 (6 H, s) 0.09 (2 H, s )0.08 (4 H,
s). 13C NMR (150 MHz, CDCl3, ppm) δ 175.03, 175.29, 151.70, 149.46, 128.38, 128.24,
69.50, 68.99, 65.46, 31.11, 23.59, 23.57, 22.60, 21.46, 21.01, 20.06, 19.54, 19.53, -0.12, 0.13.
4-(tert-Butyldimethylsilyloxy)-2,3-dimethyl-butyric acid ethyl ester (34). To a
solution of (15.4g, 56.513 mmol) unsaturated ester 33 in 110 mL dry ethyl acetate was
added (1.52g) of Pd/C 10% followed by attaching hydrogen balloon to bubble through
the solution. The reaction process was checked by TLC (Hexane 8:1 ethyl acetate), 1H
NMR, and IR to confirm the reduction process. After 4 hours 100% of the double bond
was reduced .The crude was filtered and concentrated by rotary evaporation to give
15.322g as colorless oil without purification.
5-[3-(tert-Butyldimethylsilyloxy)-1,2-dimethylpropyl]-oxazole (35). To a
stirring solution of methyl isocyanide (3.69 mL, 67.566 mmol) in 100 mL of anhydrous
THF at -78 °C was added n-BuLi (1.6 M solution in hexanes, 47.27 mL, 75.6339 mmol)
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dropwise under argon. The pale yellow creamy suspension was stirred at -78 °C for 1h, at
which time ester 34 (13.84 g, 50.4226 mmol) in anhydrous THF (20 + 20 mL, including
cannula and flask washings) was added dropwise via cannula. After stirring for 2 hours at
-78 °C, the cooling bath was removed and the solution was stirred for an additional 2
hours. The resulting brown solution was poured into 200 mL of a 1:1 water/ brine
solution and extracted with 3x200 mL ether. The combined extracts were dried (Na2SO4),
concentrated by rotary evaporation, and the residue was purified by distillation at reduced
pressure (0.5mm Hg) and short path distillation. The first drip of the colorless oil start at
73 °C to continue dripping at 80 °C .The combined fractions give 6.8399 g as a colorless
oil. Analytical TLC on silica gel 60 F254, 3:1 hexane/ ethyl Et2O, Rf= 0.29. Molecular
ion (M+H+) calcd for C14H28NO2Si: 270.1884; found m/z= 270.1909, error= 9.25 ppm;
IR (neat, cm-1) 1509; 600 MHz NMR (CDCl3, ppm) δ 7.76 (0.8 H, s) 7.75 ( 0.2 H, s)
6.75 (1 H, s) δ 3.45 (2H, m) 3.10 (1 H, p, J=6.4 Hz) 2.03 (0.3 H, quin, J=6.6 Hz ) 1.85
(0.7 H, quin, J=6.6 Hz) 1.36 (0.3 H, d, J=7.4) 1.34 (0.2 H, d, J=7.4 Hz) 1.27 (1.6 H, d,
J=7.4 Hz) 1.18 (0.9 H, d, J=7.4 Hz) 0.92 (1.2 H, d, J=2.3) 0.89 (7.8 H, d, J=3.05 Hz) 0.82
(1 H, d, J=7) 0.79 ( 1.6 H, d, J=7 Hz) 0.135 (0.9 H, s) 0.039 (5.2 H, d, J=5 Hz). 13C NMR
(150 MHz, CDCl3, ppm) δ 156.5, 155.7, 149.9, 135.9, 134.8, 122.2, 121.6, 117.7, 65.6,
40.1, 38.9, 35.0, 32.1, 31.6, 0.28.9, 25.8, 25.6, 18.2, 17.0, 16.4, 15.5, 13.4, 13.0, 12.5, 9.6,
-5.3, -5.4.
2-D- 5-[3-(tert-Butyldimethylsilyloxy)-1,2-dimethylpropyl]-oxazole (35b). To
a solution of the oxazole (33) (63.5 mg, 0.235 mmol) in 1.5 mL of anhydrous THF at 0
°C was added BH3-THF (1.0 M solution in THF, 0.26 mL, 0.26 mmol). After 5 minutes
the ice-bath was then removed and the solution was stirring at rt for 1h, the colorless
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solution was cooled to -78 °C, and n-BuLi (1.6 M solution in hexanes, 0.173 mL, 0.26
mmol) was added dropwise over 10 min. The yellow solution was stirred at -78 °C for 1
h, and then a solution MeOD (0.1 mL, 0.26 mmol) in anhydrous THF (0.5 mL, including
cannula and flask washings) was added via cannula dropwise. The resulting yellow
solution was stirred at -78 °C for 90 minutes. The reaction was quenched with 1 mL of
5% solution of AcOH in EtOH dropwise. The cooling bath was removed, and the reaction
mixture was allowed to warm to rt. After stirring at rt overnight, the resulting pale yellow
solution was concentrated by rotary evaporation to 1/4 from original volume. 3 mL of
aqueous NaHCO3 was added and then poured into 5 mL of ether, the aqueous layer was
extracted with 2 x 3 mL of ether, and all organic extracts were combined, dried (Na2SO4),
and concentrated by rotary evaporation.
2-[(lR,2S) and (lS,2S)-3-Allyloxy-l-hydroxy-2-tritylaminopropyl)-5-[(1R) and
(1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole (39) To a
solution of the oxazole (35) (1.55 g , 5.75 mmol) in 20 mL of anhydrous THF at 0 °C was
added BH3-THF (1.0 M solution in THF,6.32 mL, 6.32 mmol). After 5 minutes the icebath was then removed and the solution was stirring at rt for 1h, the colorless solution
was cooled to -78 °C, and n-BuLi (1.6 M solution in hexanes, 3.95 mL, 6.32 mmol) was
added dropwise over 10 min. The yellow solution was stirred at -78 °C for 1 h, and then a
solution of the aldehyde 38 (2.136 g, 5.75 mmol) in anhydrous THF (20 mL, including
cannula and flask washings) was added via cannula dropwise. The resulting yellow
solution was stirred at -78 °C for 2 h, then slowly warmed to reach 0°C within additional
2 h. The reaction cooled back to -78 °C, and then quenched with 20 mL of 5% solution of
AcOH in EtOH dropwise. The cooling bath was removed, and the reaction mixture was
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allowed to warm to rt. After stirring at rt for 21 h, the resulting pale yellow solution was
concentrated by rotary evaporation to 1/3 from original volume, 40 mL of aqueous
NaHCO3 was added and then poured into 100 mL of ether + 100 mL of H2O, The
aqueous layer was extracted with 2 x 50 mL of ether, all organic extracts were combined,
washed with 100 mL of brine, dried (Na2SO4), and concentrated by rotary evaporation.
The residue was purified by flash chromatography on silica gel (25x14 cm, 10:1
hexane/acetone eluent, followed by 5:1 hexane/acetone eluent 20 mL fractions). Fractions
26-38 were concentrated to give the amino alcohol 39 Fractions 7-10 were concentrated
and repurified by flash chromatography on silica gel (25x8 cm, 10:1 hexane/acetone
eluent, followed by 5:1 hexane/acetone eluent 10 mL fractions). Fractions 15-20 were
concentrated to give the amino alcohol 39.The combined purified 39 give 3.001 g as a
pale yellow very sticky oil. Analytical TLC on silica gel 60 F254, 5:1 hexane/ether, Rf=
0.30. Molecular ion (M+H+) calcd for C39H53N2O4Si: 641.3769; found m/z= 641.3679,
error= 14 ppm; IR (neat, cm-1) 1563; 600 MHz NMR (CDCl3, ppm) δ 7.58-7.48 (6 H,
m) 7.22 (6 H, m) 7.15 (3 H, m) 6.64-6.55 (1 H, s) 5.75-5.58 (1 H, m) 5.71-4.98 (2 H, m)
4.53-4.44 (1 H, m) 3.51 (2 H, d, J=5.3 Hz) 3.46-3.35 (2 H, m) 3.283.21 (1 H, br) 3.093.96 (1 H, m) 2.90-2.79 (1 H, m) 2.69-2.47 (1 H, br) 2.44-2.33 (1 H, m) 2.10-1.96 (0.4 H,
m) 1.86-1.73 (0.6 H, m) 1.24-1.20 (1 H, dd, J=7.3,3.3 Hz) 1.16 (1 H, d, J=6.10 Hz)1.131.10 (1 H, dd, J=4.4,2.7 Hz) 0.86 (6 H, s) 0.83 (3 H, s) 0.79 0.71 (3 H, m) 0.043 (0.5 H,s)
0.05-0.01 (5.5 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ 162.98, 162.94, 162.86,
162.83, 156.88, 156.82, 155.80, 155.78, 146.61, 146.50, 134.25, 128.76, 128.71, 127.99,
127.91, 126.57, 122.35, 121.84, 116.93, 116.89, 71.89, 70.92, 70.90, 69.37, 69.35, 69.24,
69.15, 69.01, 68.93, 65.79, 65.68, 65.65, 64.33, 54.98, 54.95, 54.92, 40.17, 40.10, 38.70,
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38.69, 32.50, 32.48, 31.74, 31.71, 25.94, 25.39, 18.28, 16.51, 16.44, 13.96, 13.93, 12.73,
12.65, 12.41, 12.36, 1.06, -5.35, -5.38, -5.4135.
2-[(2S,3R)-3-Allyloxymethyl-1-trityl-aziridin-2-yl]-5-[(1R) and (1S) , (2R) and
(2S)- tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole (40)
To a solution of amino alcohol 39 (2.922 g, 4.56 mmol) in 42 mL anhydrous THF
at 0 °C was added Ph3P (2.45 g, 9.34 mmol), followed by diethyl azodicarboxylate (1.436
mL, 9.12 mmol) dropwise. The cooling bath was removed, and the reaction mixture was
allowed to warm to rt. After stirring at rt for 30 h, the yellow solution was concentrated
by rotary evaporation. The residual oil was dissolved in 1 mL of CH2Cl2 and purified by
flash chromatography on silica gel (25x14, 3:1 hexane/EtOAc eluent, 15 mL fractions).
Fractions 6-15 were concentrated to yield poor purified product, and the residue was
purified by another flash chromatography on silica gel (25x14, 5:1 hexane/EtOAc eluent,
15 mL fractions). Fractions 28-48 were concentrated to give 2.457 g ( 86%) as a pale
yellow to colorless oil, analytical TLC on silica gel 60 F254, 3:1 hexane/EtOAc, Rf=
0.36. Molecular ion (M+H+) calcd for C39H51N2O3Si: 623.3663; found (electrospray)
m/z= 623.3682, error= 3 ppm; IR (neat, cm-1) 1570; 600 MHz NMR (CDCl3, ppm) δ 7.58
(6 H, m) 7.30 (6 H, m) 7.26 ( 3 H, m) 6.78 (1 H, s) 5.84-5.73 (1 H, dddd, J= 17.3,10.4,
5.5,5.5 Hz)5.20 (1 H, dddd, J= 17.3,10.4, 5.5,5.5 Hz) 5.10 (1 H, dddd, J= 10.3,10.4,
5.5,5.5 Hz) 4.07 (1 H, m) 3.88-3.73 (3 H, m) 3.63-3.48 (2 H, m) 3.19-3.11 (1 H, m) 2.54
(1 H, dd, J=2.64 Hz) 2.22-2.09 (0.3 H, m) 2.02-1.90 (1.7 H, m) 1.36 (2 H , dd, J=2.46
Hz) 1.25 (1 H, dd, J=2.64 Hz) 0.98 (9 H, s) 0.93-0.87 (3 H, m) 0.15 (3 H, s) 0.13 (1.7 H,
s) 0.08 (1.8 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ 160.35, 156.72, 155.79, 155.57,
143.78, 134.67, 129.58, 129.33, 128.94, 127.97, 127.76, 127.37, 127.01, 123.22, 122.60,
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116.99, 116.95, 75.08, 71.95, 71.90, 68.60, 68.57, 65.98, 65.87, 40.53, 40.29, 39.13,
38.94, 38.54, 26.05, 18.41, 16.86, 16.78, 13.87, 13.71, 13.22, 12.74, 12.41, -5.22, 5.2479.
2-[(2S,3R)-3-Allyloxymethylaziridin-2-yl]-5-[(1R) and (1S) , (2R) and (2S)tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole (41). To a solution of the Traziridine 40 (7.5 g, 12.040 mmol) in 100 mL dry DCM at 0°C was added
triethylhydrosilane (7.953 mL, 49.245 mmol) followed by adding trifluoroacetic acid
(3.932 mL, 51.049 mmol). After stirring at 0 °C for 80 minutes, triethylamine (7.887 mL,
56.588 mmol) was added dropwise, the ice bath was then removed to let the solution to
stir additional 20 minutes. Poured into 320 mL of DCM, and washed with 2x250 mL of
saturated aqueous NaCl, dried over (Na2SO4), and concentrated by rotary evaporation.
The residue was purified by flash chromatography on silica gel (25x18.5 cm, 3:1 hexane/
acetone eluent, 25 mL fractions). Fractions 18-47 were concentrated to give 3.879 g
(84%) as a clear colorless oil, analytical TLC on silica gel 60 F254, 3:1 hexane/acetone,
Rf= 0.29. Molecular ion (M+H+) calcd for C20H37N2O3Si: 381.2568; found (electrospray)
m/z= 381.2589, error= 7 ppm; IR (neat, cm-1) 3242, N-H; 1572; 300 MHz NMR (CDCl3,
ppm) 6.65 (1 H, s) 5.81 (1 H, m) 5.16 (1 H, dddd, J=7.45, 1.4,1.4,1.4 Hz) 5.08 (1 H,
dddd, J=10.3, 1.4,1.4,1.4 Hz) 3.90 (2 H, br) 3.64-3.51 (2 H, m) 3.49-3.37 (2 H, m) 3.142.96 (1 H, m)2.80-2.44 (1 H, d, J=43.82 Hz) 2.02 ( 0.5 H, br) 1.82 (0.5 H, br)1.5-1.29 (2
H, m) 1.25-1.12 (3 H, dd, J=15.3, 6.95 Hz) 0.97 (6 H,s) 0.85 (3 H,s) 0.81-0.76 (2.6 H, m)
0.60-0.52 (0.4 H, m) ) 0.12-0.02 (6 H, s) .13C NMR (75 MHz, CDCl3, ppm) δ 159.51,
159.44, 156.91, 156.00, 134.45, 122.68, 117.12, 71.90, 69.23, 68.14, 65.67, 65.57, 40.01,
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38.66, 37.69, 36.06, 35.07, 32.32, 31.67, 30.89, 29.64, 25.87, 25.62, 18.23, 16.51, 13.80,
12.79, 12.36, 6.77, 4.35, -5.42, -5.45, -5.4999.
2-[(2S,3R)-3-Allyloxymethyl-1-methyaziridin-2-yl]-5-[(1R) and (1S) , (2R)
and (2S)- tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole (42). To a solution
of H-Aziridine 41 (1.1 g, 2.89 mmol) in 23.5 mL dry THF at -78 °C under argon was
added n-BuLi (1.60 M solution in hexanes, 2.02 mL, 3.237 mmol) was added dropwise.
The yellow solution was stirred at -78 °C for 30 minutes .to the resulting brown solution
MeI (0.216 mL, 3.468 mmol) was added dropwise, then the cold bath was removed and
the reaction mixture was allowed to warm to rt. After 1h at rt, the resulting solution
poured into 100 mL of Et2O, and washed with 2 x 100 mL brine dried over (Na2SO4), and
concentrated by rotary evaporation. The residue was purified by flash chromatography on
silica gel (25x8 cm, 5:1 hexane/ acetone eluent, 15 mL fractions). Fractions 11-20 were
concentrated to give 0.956 g of product as yellow oil. Analytical TLC on silica gel 60
F254, 5:1 hexane/acetone, Rf= 0.31. Molecular ion (M+H+) calcd for C21H39N2O3Si:
395.2724; found (electrospray) m/z= 395.2742, error= 5 ppm; IR (neat, cm-1) 1572; 600
MHz NMR (CDCl3, ppm) δ 6.65 (1 H, S) 5.85 (1 H, m) 5.2 (1 H, dddd, J=17.25,1.4,
1.4,1.4 Hz) 5.14 (1 H, dddd, J=10.4,1.4, 1.4,1.4 Hz) 3.98-3.88 (2 H, m) 3.66 (1 H, m)
3.57 (1 H, m) 3.50-3.38 (2 H, m) 3.11-2.97 (1 H, m) 2.62-2.58 (1 H, m) 2.54 (3 H, s)
2.08-1.98 (1.5 H, m) 1.82 ( 0.7 H, ddd, J=6.24, 6.0, 6.0 Hz) 1.23 (2 H, dd,, J=3.35 Hz)
1.13 (1 H, dd, J=2,88,4.24 Hz) 0.97 (6 H, s) (.91 (2 H, s) 0.88 (1 H, s) 0.79 (3 H, m) 0.58
( 0.5 H, ddd, J=4.9,3.2, 3.2 Hz) 0.34 (3, H, s) 0.34 (3H, s). 13C NMR (150 MHz, CDCl3,
ppm) δ 164.81, 162.26, 161.40, 161.22, 140.04, 128.27, 128.24, 127.89, 122.48, 122.45,
77.33, 74.10, 74.83, 70.99, 52.87, 51.82, 51.7, 45.34, 44.78, 44.73, 44.71, 44.04, 44.00,
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37.97, 37.13, 31.3, 23.68,21.96, 21.70, 19.45, 19.33, 18.35, 17.98, 17.84, 17.69, 12.25,
12.24, 9.81, 0.00
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S)-3-tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazol-2-yl)-3-hydroxymethyl-1-methylaziridine (43). A solution of
zirconocene dichloride (Aldrich, 341 mg, 1.167 mmol) in 9 mL of anhydrous THF was
cooled to -78 °C, and n-BuLi (1.6 M solution in hexanes, 1.556 mL, 2.499 mmol) was
added dropwise. After the resulting yellow solution was stirred at -78 °C for 1 h, a
solution of the allyl ether 42 (307 mg, 0.778 mmol) in anhydrous THF (9 mL, including
cannula and flask washings) was added dropwise via cannula. The yellow solution was
stirred at -78 °C for 5 min, the cooling bath was removed, and the reaction mixture was
allowed to warm to rt. After 1 h, the resulting dark brown solution was cooled to 0 °C,
and 9 mL of saturated aqueous NH4Cl was added. The resulting suspension was stirred at
rt for 2 h and then filtered through Celite (3x5 cm) eluting with 80 mL of ether. The
filtrate was washed with 2x40 mL of brine, dried (Na2SO4), and concentrated by rotary
evaporation. The residue was purified by flash chromatography on silica gel (25x8cm,
2:1 hexane/acetone eluent, 15 mL fractions). Fractions 14-30 furnished 228 mg (83%) of
the product as a pale yellow oil, analytical TLC on silica gel 60 F254, 2:1
hexane/acetone, Rf= 0.3. Molecular ion (M+H+) calcd for C18H35N2O3Si: 355.2411;
found (electrospray) m/z= 355.2491, error= 22 ppm; IR (neat, cm-1) 3339, O-H; 1571;
600 MHz NMR (CDCl3, ppm) δ 6.63 (1 H, S) 3.39 (1 H, ddd, J=12.5 6.3, 5.9 Hz) 3.8 (1
H, dd, J=6.6, 6.5 Hz) 3.64 ( 1 H, dd, J=10.5 Hz) 3.51-3.41(2 H, m) 3.05 (1 H, m) 2.55 (3
H, s) 2.52 (1 H, d, J=6.4 Hz) 2.11 (1 H, ddd, J=6.0, 6.0, 6.0 Hz) 2.03 (0.4 H, m) 1.86 (0.8
H, m) 1.25 (2 H, d, J=7.17 Hz) 1.15 (0.8 H,d, J=7.17 Hz) 0.90 (9 H, s) 0.80 (3 H, dd,
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J=2.9,4.10) 0.04 (3 H, s) 0.0358 (3 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ 165.10,
162.98, 161.95, 127.7, 127.25, 71.16, 71.02, 66.68, 66.59, 52.97, 52.7, 45.41, 44.61,
44.11, 37.82, 37.16, 31.33, 23.70, 21.71, 19.12, 18.23, 18.19, 17.84, 17.81, 12.23, 9.79,
0.00
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3-tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1-methylaziridine (44). A solution of Ph3P
(260 mg, 0.99 mmol) in 6 mL of anhydrous toluene was cooled to 0 °C, and diethyl
azodicarboxylate (0.156 mL, 0.99 mmol) was added, followed by a solution of the
alcohol 43 (228 mg, 0.640 mmol) in anhydrous toluene (3 mL, including cannula and
flask washings), followed by MeI (0.06 mL, 0.99 mmol). After stirring the resulting
white suspension at 0 °C for 5 min, the cooling bath was removed, and the reaction
mixture was heated at 70°C for 2 h. The precipitate dissolved forming a yellow solution,
which was concentrated to approximately 1 mL by rotary evaporation. The residual liquid
was purified by flash chromatography on silica gel (25x8 cm, 3:1 hexane/acetone eluent,
15 x 15 mL fractions). Fractions 8-12 were concentrated to give 260 mg (87) of pure (37)
as a clear colorless oil, analytical TLC on silica gel 60 F254, 3:1 hexane/acetone, Rf=
0.45. Molecular ion (M+H+) calcd for C18H34IN2O2Si: 465.1429; found (electrospray)
m/z= 465.1533, error= 22 ppm; IR (neat, cm-1) 1571; 600 MHz NMR (CDCl3, ppm) δ
6.68 (0.7 H, s) 6.66 (0.3 H, s) 3.52-3.38 (3 H, m) 3.30-3.19 (1 H, m) 3.12-2.96 (1 H, m)
2.78 (1 H, td, J=2.55, 1.0 Hz) 2.54 (3 H, s) 2.30-2.20 (1 H, m) 2.03 (0.3 H, m) 1.91-1.77 (
0.7 H, m) 1.25 (2 H, d, J=7.23 Hz) 1.15 (1 H, d, J=7.1 Hz) 0.89 (9 H, s) 0.84-0.77 ( 3 H,
m) 0.08-0.009 (6 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ 158.57, 157.20, 156.26,
156.17, 123.04, 123.02, 122.61, 122.48, 77.45, 77.03, 76.60, 65.75, 65.63, 65.60, 49.05,
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48.97, 47.30, 44.14, 44.11, 44.06, 40.05, 39.96, 38.68, 32.50, 32.40, 31.74, 25.91, 18.27,
16.50, 16.31, 13.91, 13.79, 13.00, 12.74, 12.52, 12.43, 6.83, 4.40, 3.61, 3.55, 3.47, -5.37,
-5.403.
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3-hydroxy-1,2dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1-methylaziridine (45). To a solution of
the silyl ether 44 (250 mg, 0.538 mmol) in 4 mL of anhydrous CH3CN at rt was added
HF-pyridine (ca.70% HF, 0.18 mL, 7 mmol). After stirring at rt for 45 minutes, then
quenched with 4 mL of saturated aqueous NaHCO3. The resulting solution was poured
into 25 mL of saturated aqueous NaHCO3 and extracted with 2x25 mL of CH2Cl2. The
combined organic extract was dried (Na2SO4),Filtered then concentrated by rotary
evaporation, and the residue was purified by flash chromatography on silica gel (28x8
cm, 3:2 hexane/acetone eluent, 15 mL fractions). Fractions 12-20 gave 170 mg (90%) of
the desired product as a yellow oil, analytical TLC on silica gel 60 F254, 3:2
hexane/acetone, Rf= 0.2. Molecular ion (M+H+) calcd for C12H20IN2O2: 465.1429; found
(electrospray) m/z= 465.1533, error= 3 ppm; IR (neat, cm-1) 3360, O-H; 1569; 600 MHz
NMR (CDCl3, ppm) δ 6.671 (1 H, S) 3.57 (2 H, m)3.41 (1 H, m) 3.27-3.20 (1 H, m) 3.113.01 (1 H, m) 2.7 (1 H, t, J=6.9) 2.55 (3 H, s) 2.27 (1 H, m) 2.06-1.89 (1 H, m) 1.27 (2 H,
dd, J=4.5,2.75) 1.20 (1 H, dd, J=5.7,1.3) 0.87 (3 H, ddd, J=6.25). 13C NMR (150 MHz,
CDCl3, ppm) δ 158.64, 158.61, 156.80, 155.85, 155.77, 123.18, 123.17, 122.70, 122.56,
65.73, 65.62, 49.04, 48.99, 47.26, 47.21, 44.09, 44.04, 39.92, 39.86, 32.47, 32.20, 16.13,
13.45, 12.89, 3.56.
(2S,3R)-3-Iodomethyl-1-methyl-2-(5-[(1R) and (1S), (2R) and (2S) -1,2dimethyl-3-oxopropyl]oxazol-2-yl)aziridine (46). To a solution of the alcohol 45 (147

55
mg, 0.420 mmol) in 3 mL of CH2Cl2 at °C was added Dess-Martin periodinane (285 mg,
0.670 mmol) followed by adding drop of H2O and the resulting milky suspension was
stirred at rt for 2 h. 8 mL of aqueous NaHCO3-Na2S2O3 (5% NaHCO3, 15% Na2S2O3)
was added and the resulting solution was stirred for an additional 20 minutes. The
reaction mixture was poured into 25 mL of aqueous NaHCO3-Na2S2O3 (5% NaHCO3,
15% Na2S2O3) and extracted with 2x50 mL of CH2Cl2. The combined organic extract was
dried (Na2SO4) and concentrated by rotary evaporation and the residue was purified by
flash chromatography on silica gel (28x8 cm, 3:1 hexane/acetone eluent, 20 mL
fractions). Fractions 13-23 gave 114 mg (78%) of product as a pale yellow oil, analytical
TLC on silica gel 60 F254, 3:1 hexane/acetone, Rf= 0.11. Molecular ion (M+H+) calcd
for C12H18IN2O2: 349.0408; found (electrospray) m/z= 349.0417, error= 3 ppm; IR (neat,
cm-11723, C=O; 1570; 600 MHz NMR (CDCl3, ppm) δ 9.73 (0.23 H, d, J=1.3 Hz) δ 9.71
(0.35 H, d, J=1.3 Hz) δ 9.73 (0.3 H, d, J=0 Hz)) 6.76 (0.6 H, s) 6.7 (0.4 H, s) 3.48-3.31 (2
H, m) 3.22 (1 H, ddd, J=2.95 Hz) 2.82-2.61 (2 H, m) 2.56 (3 h, d, J=4.9 Hz) 2.28 (1 H,
quin, J=6.2 Hz) 1.33 (2 H, dd, J=3.3 Hz) 1.23 (1 H, dd, J=2.75 Hz) 1.08 (1 H, t, J=7.5
Hz) 1.03 (2 H, dd, J=7.00 Hz). 13C NMR (150 MHz, CDCl3, ppm) δ 203.38, 203.27,
203.17, 203.13, 159.34, 159.27, 159.16, 154.76, 154.14, 154.76, 123.72,123.62, 123.46,
123.38, 50.42, 50.24, 49.33, 49.25, 49.16, 48.99, 47.27, 47.24, 43.93, 43.92, 43.75, 31.97,
31.77, 30.97, 30.89, 16.27, 16.18, 13.91, 13.65, 10.88, 10.59, 9.37, 9.28, 3.41, 3.40, 3.30.
(2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R) ,((1S,2R,3R), (1S,2S,3S)
(1R,2S,3S), (!R,2R,3S),(1S,2S,3R)-3-hydroxy-1,2-dimethyl-6-tertbutyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1-methylaziridine (47).
A solution of tert-butyldimethylsilyl propargyl ether29 (838 mg, 4.92 mmol) in 38 mL of

56
anhydrous THF was cooled to -40 °C (Dry Ice-CH3CN bath), and n-BuLi (1.6 M solution
in hexanes, 3.07 mL, 4.92 mmol) was added dropwise. The yellowish solution was stirred
at -40 °C for 1 h. The aldehyde 46 obtained as above (952 mg, 2.734 mmol) was
dissolved in anhydrous THF (50 mL, including cannula and flask washings) and added
dropwise via cannula. After stirring at -40 °C for 2 h, 20 mL of saturated aqueous
NaHCO3 was added, the cooling bath was removed and the reaction was stirred an
additional 5 minutes. Poured into 200 mL NaHCO3, extracted with 3x350 mL CH2Cl2.
The combined organic extracts were dried (Na2SO4), concentrated by rotary evaporation,
and the residue was purified by flash chromatography on silica gel (28x8 cm, 2:1
hexane/acetone eluent, 20 mL fractions). Fractions 9-17 gave 1.33 g (93%) of the desired
alcohol as a pale yellow oil, analytical TLC on silica gel 60 F254, 2:1 hexane/acetone,
Rf= 0.31. Molecular ion (M+H+) calcd for C21H36IN2O3Si: 519.1534; found
(electrospray) m/z= 519.1562, error= 5 ppm; IR (neat, cm-1) 3291, C=H; 1571; 600 MHz
NMR (CDCl3, ppm) δ 6.73 (1 H, s) 4.36 (2 H, m) 3.51-3.42 (1 H, m) 3.30-3.13 (2 H, m)
2.83 2.77 (1 H, m) 2.56 (3 H, s) 2.33 1.85 (3 H, m) 1.33-1.21 (3 H, m) 1.06-0.93 (3 H m)
0.922 (7 H, s) 0.91 (2 H, s) 0.14 (3.5 h, s) 0.12 (2.5 H, s). 13C NMR (150 MHz, CDCl3,
ppm) δ 158.83, 158.76, 155.65, 155.59, 123.31, 123.29, 122.94, 122.81, 84.90, 84.86,
84.72, 84.67, 84.65, 83.98, 64.88, 64.83, 64.79, 64.61, 64.47, 51.73, 51.70, 49.09, 49.01,
48.97, 47.29, 47.26, 44.02, 43.98, 43.89, 43.85, 43.81, 33.15, 25.80, 17.12, 17.01, 14.28,
13.52, 11.94, 11.90, 11.17,3.58,3.49,3.40, -5.10.
(2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R), ((1S,2R,3R), (1S,2S,3S)
(1R,2S,3S), (1R,2R,3S),(1S,2S,3R)-3-Acetoxy-1,2-dimethyl-6-tertbutyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1-methylaziridine (48).
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To a solution of alcohol 47 (1.331 g, 2.567 mmol) in 36 mL dry CH2Cl2 was added at rt
Et3N (1.789 mL, 12.837 mmol) dropwise, followed by Ac2O (0.482 mL, 5.135 mmol),
followed by DMAP (125 mg, 1.020 mmol). The resulting solution was stir at rt for 1h. 9
mL MeOH was added, the resulting brown solution was stirred at rt for additional 10
minutes. Poured into 300 mL Et2O, washed with 2x300 mL brine. The organic layer were
dried (Na2SO4), concentrated by rotary evaporation, and the residue was purified by flash
chromatography on silica gel (28x8 cm, 4:1 hexane/acetone eluent, 10 mL fractions).
Fractions 7-17 gave 1.213 g (84%) of the desired acetate as a pale yellow oil, analytical
TLC on silica gel 60 F254, 4:1 hexane/acetone, Rf= 0.2.6. Molecular ion (M+H+) calcd
for C23H38IN2O4Si: 561.1640; found (electrospray) m/z= 561.1721, error= 14 ppm; IR
(neat, cm-) 1742, C=O; 1571; 600 MHz NMR (CDCl3, ppm) δ 6.74 (0.2 H, s) 6.72 (0.3 H,
s) 6.69 (0.5 H, s) 5.46-5.22 (1 H, m) 4.34 (2 H, s) 3.50-3.38 (1 H, m) 3.30-2.97 (2 H, m)
2.82-2.74 (1 H, m) 2.55 (3 H, s) 2.29-2.05 (5 H, m) 1.311.18 (3 H, m) 1.02-0.92 93 H, m)
0.90 (9 H, s) 0.11 (6 H,s). ). 13C NMR (150 MHz, CDCl3, ppm) δ169.79, 169.66, 169.63,
158.96, 158.93, 158.88, 155.94, 155.90, 155.59, 155.04, 155.02, 154.92, 123.47, 123.42,
123.36, 51.65, 51.63, 49.13, 49.08, 49.04,49.03, 49.00, 48.95, 48.93, 47.26, 47.22, 44.20,
44.16, 44.11, 44.01, 43.97, 43.94, 43.90, 42.01, 41.99, 41.11, 41.08, 40.72, 40.67, 40.19,
39.98, 33.16, 33.07, 33.03, 32.98, 32.53, 32.50, 32.33, 32.15, 25.75, 20.98, 20.95, 20.92,
20.86, 18.22, 17.37, 17.13, 16.85, 16.53, 14.05, 13.61, 13.54, 13.42, 12.81, 12.73, 12.60,
11.64, 11.57, 11.47, 11.42, 3.68, 3.60, 3.56, 3.46, 3.42, -0.0002
(1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R) ,((1S,2R,8R), (1S,2S,8S)
(1R,2S,8S), (1R,2R,8S),(1S,2S,8R)-8-Acetoxy-9-(tert-butyldimethylsilyloxymethyl)2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2-(N-methylaziridino)-5-oxo-1H-pyrrolo[1,2-
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a]indole (49). A solution of 48 (260 mg, 0.463 mmol) in 4.5 mL of anhydrous CH3CN
was transferred via cannula into a 10 mL round bottom flask, charged with silver triflate
(190 mg, 0.742 mmol), and supported with condenser. The resulting solution was heated
in an oil bath at 70 °C under N2 for 6h. A tan solution containing a yellow precipitate of
AgI formed as the reaction mixture was heated. The resulting dark brown reaction
mixture was cooled to rt, and the supernatant solution was carefully transferred via
cannula (2.5 mL CH3CN used to wash to transfer) dropwise into a stirred suspension of
BnMe3N+CN– (327 mg, 1.855 mmol) in 7.5 mL of anhydrous CH3CN at rt. After stirring
at rt for 45 min, the brown solution was poured into 60 mL of brine and extracted with
3x100 mL CH2Cl2. The organic extract was dried (Na2SO4), concentrated by rotary
evaporation, and the residue was purified by flash chromatography on silica gel treated
with Et3N (11x5 cm, 50 mL/50 mL/0.5 mL hexane/EtOAc/Et3N eluent, 5 mL fractions).
Fractions 6-16 gave 44 mg (60%) purity of the 49, Fractions 14-17 give17 mg of (90%)
purity of the 49 as a pale yellow oil. Analytical TLC on silica gel 60 F254 pretreated with
NEt3 (5 min in a chamber saturated with NEt3 vapor), neat EtOAc eluent, Rf= 0.7.
Molecular ion (M+H+) calcd for C23H37N2O4Si: 561.1640; found (electrospray) m/z=
561.1721, error= 9 ppm; 600 MHz NMR (CDCl3, ppm) δ 6.29-5.78 (1 H, m) 4.74-4.59 (2
H, m) 4.42-4.28 (1 H, m) 4.18-4.4.06 (1 H, m) 3.06 -2.95 (1 H, m) 2.64-2.51 (1 H, m) 2.4
7-2.38 (3 H, m) 1.251.04 (3 H, m) 0.95 (9 H, s) 0.943-0.89 (3 H ,m) 0.16 (1.5 H, S) 0.13
(1.5 H, S) 0.1 (1.5 H, S) 0.7 (1.5 H, S). 13C NMR (150 MHz, CDCl3, ppm) δ 190.05,
170.47, 170.30, 141.34, 140.76, 130.82, 129.36, 123.68, 123.00, 117.07, 116.45, 106.42,
71.15, 70.04, 69.85, 57.83, 57.78, 57.65, 57.52, 49.91, 49.85, 47.98, 47.93, 47.84, 47.63,
46.88, 45.59, 45.44, 44.61, 44.59, 42.38, 41.60, 40.99, 40.92, 40.84, 26.01, 25.75, 21.23,
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21.05, 21.01, 18.432, 18.40, 17.38, 15.64, 12.96, 11.55, 11.49, -0.0079, -5.2818, -5.2943,
-5.3607.
(1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R) ,((1S,2R,8R), (1S,2S,8S)
(1R,2S,8S), (1R,2R,8S),(1S,2S,8R)-8-Hydroxy-9-(tert-butyldimethylsilyloxymethyl)2,3,5,6,7,8 hexahydro-6,7-dimethyl-1,2-(N-methylaziridino)-5-oxo-1H-pyrrolo[1,2a]indole (50). A 10 mL pear shaped flask was charged with the acetate 49 (140 mg,
0.3235 mmol), and 1% solution of NaOH in MeOH (3.3 mL) was added. After stirring at
rt for 1 h, the pale tan solution was poured into 15 mL of 50% brine and extracted with
3x30 mL of CH2Cl2. The combined organic extract was dried (Na2SO4), concentrated by
rotary evaporation to give a brown oil (124 mg), and the residue was carried on to the
next reaction without further purification to prevent decomposition of the compound
during chromatography.
(1S,2S,6S,7S) and (1S,2S,6R,7R) (1S,2S,6S,7R) and (1S,2S,6R,7S)-9-(tertButyldimethylsilyloxymethyl)-5,8-dioxo-2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2-(Nmethylaziridino)-1H-pyrrolo[1,2-a]indole (51) To a solution of alcohol 50 (124 mg,
0.317 mmol) and N-methylmorpholine N-oxide (74.45 mg, 0.6355 mmol) in 24.0 mL of
anhydrous CH2Cl2 was added (0.870 g) of 4Å molecular sieves (<5 micron powder
activated at 150 C and 0.5 mm Hg vacuum for 10 h) in one portion. After stirring the
white suspension at rt for 5 min, tetrapropylammonium perruthenate (27.91 mg, 0.0790
mmol) was added in one portion. The resulting blackish suspension was stirred at rt for 1
h, and then quickly filtered through silica (0.5x2 cm) eluting with 15 mL of EtOAc. The
filtrate was concentrated by rotary evaporation, and the residue was purified by flash
chromatography on silica gel (11x5 cm, neat EtOAc eluent, 10 mL fractions). Fractions
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3-6 gave 87 mg (48% from the starting acetate) of the diketone as a pale yellow oil. All
chromatography operations were carried out as fast as possible. Analytical TLC on silica
gel 60 F254, EtOAc, Rf= 0.45 and 0.42. Molecular ion (M+H+) calcd for C21H33N2O3Si:
389.2255; found (electrospray) m/z= 389.2288, error= 8 ppm; 600 MHz NMR (CDCl3,
ppm) δ 5.00 (1 H, AB q, J=14.7Hz) 4.95 (1 H AB q, J=14.7 Hz) 4.35 (1 H, d,
J=14.00,15.6 Hz) 4.16-4.08 (1 H, m) 3.13 (1 H, d, J=5.1 Hz) 3.02-2.93 (1 H, m) 2.86 (1
h, dd, J=4.15,4.41 Hz) 2.65-2.56 (1 H, m) 2.44 (3 H, s) 1.29-1.26 (4 H, m) 1.14 (2 h, d,
J=6.3 Hz) 0.96 (9 H, s) 0.14 (3 H, s) 0.134 (3 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ
197.75, 196.84, 191.49, 190.49, 190.38, 141.36, 141.13, 128.47, 128.40, 126.96, 126.88,
126.79, 119.25, 119.20, 119.15, 59.31, 59.29, 59.20, 50.83, 50.65, 49.78, 49.76, 49.67,
49.61, 49.55, 48.96, 48.16, 47.70, 47.55, 44.58, 41.13, 26.06, 18.41, 16.16, 16.12, 15.98,
15.91, 13.52, 13.35, 0.002, -5.32, -5.4118.
(1S,2S)-9-(tert-Butyldimethylsilyloxymethyl)-2,3-dihydro-6,7-dimethyl-1,2(N-methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (52). A 10 mL flask was
charged with the diketone 51 (34 mg, 0.0874 mmol) and N,N'bis(salicylidene)ethylenediaminocobalt (II) (Aldrich, 5.6 mg, 0.01740 mmol), and filled
with O2 (balloon). A solution of 1,4-diazabicyclo[2.2.2]octane (DABCO, 0.112 mg,
1.006 mmol) in anhydrous CH3CN (3.5 mL, including cannula and flask washings) was
added via cannula under a stream of O2. The resulting dark brown, blackish suspension
was stirred under O2 (balloon) at rt. After 2.5 h, the reaction mixture was concentrated by
rotary evaporation, and the residue was purified by flash chromatography on silica gel
(11x5 cm, neat EtOAc eluent, 10 mL fractions). Fractions 3-8 gave 31 mg as a mixture of
the product and the starting diketone. The combined fractions was purified again by
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preparative TLC on silica gel (20x20x0.025 cm, 1:1 hexane/ethyl acetate eluent) to give
12 mg (35%) of the product as an orange crystal. Analytical TLC on silica gel 60 F254,
EtOAc, Rf= 0.6. Molecular ion (M+H+) calcd for C21H31N2O3Si: 387.2098; found
(electrospray) m/z= 387.2134, error= 9 ppm; 600 MHz NMR (CDCl3, ppm) δ 5.01 (1 H,
AB q, J=15 Hz) 4.99 (1 H,AB q, J=15Hz) 4.32 (1 H, d, J=13.82 Hz) 4.12-4.08 (1 H, dd,
J=9.84,3.97 Hz) 3.10 (1 H, d, J=5 Hz) 2.84 (1 H, d, J=4.4, 3.8 Hz) 2.43 (3 H, s) 1.98 (3
H, s) 1.94(3 H, s) 0.96 (9 H, s) 0.15 (3 H, s) 0.875 (3 H,s). 13C NMR (150 MHz, CDCl3,
ppm) δ 183.92, 177.53, 141.22, 140.02, 139.46, 126.52, 123.89, 120.26, 59.41, 49.61,
47.70, 44.59, 41.17, 26.06, 18.43, 12.36, 11.89, 1.02, -0.0008, -5.33, -5.4263.
(1S,2S)-2,3-Dihydro-9-hydroxymethyl-6,7-dimethyl-1,2-(N-methylaziridino)1H-pyrrolo[1,2-a]indole-5,8-dione (53). The HF-NEt3 reagent was prepared by
dropwise addition of HF-pyridine (ca. 70% HF, 0.10 mL, 3.9 mmol) to a solution of NEt3
(1.4 mL, 10.0 mmol) in 3.0 mL of anhydrous CH3CN (mildly exothermic process). 0.28
of the resulting HF-NEt3 reagent (0.242 mmol of HF, 0.622 mmol of NEt3) was added to
a solution of the silyl ether 52 (28 mg, 0.0724 mmol) in 2 mL of anhydrous CH3CN at rt.
After stirring at rt for 11 h, the solution had turned brown and an intractable solid had
formed. The brown solution was poured into 20 mL of brine and extracted with 4x15 mL
of CH2Cl2. The combined organic extract was dried (Na2SO4), concentrated by rotary
evaporation, and the residue was purified by flash chromatography on silica gel (11x5
cm, neat EtOAc eluent, then 10:1 CH2Cl2/MeOH eluent 10 mL fractions). Fractions 1012 gave 12 mg (60%) of the product as a red crystals. Fractions 3-5 give 8 mg as a
starting silyl ether 52 (28%). Analytical TLC on silica gel 60 F254, 10:1 CH2Cl2/MeOH,
Rf= 0.56. Molecular ion (M+H+) calcd for C15H17N2O3: 273.1233; found (electrospray)
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m/z= 273.1283, error= 18 ppm; 600 MHz NMR (CDCl3, ppm) δ 4.80 (1 H, dd, J=13.48,
5.2 Hz) 4.66 (1 H, dd, J=13.48, 7.1 Hz) 4.36 (1 H, d, J=13.38 Hz) 4.28-4.17 (1 H, br)
4.16 (1 H, dd, J=4.6, 3.86 Hz) 2.94 (1 H, dd, J=4.7, 3.97 Hz) 2.90 (1 H, d, J=5.03) 2.47 (3
H, s) 2.05 (3 H, s) 2.03 (3 H, s). 13C NMR (150 MHz, CDCl3, ppm) δ 184.98, 177.43,
141.38, 140.07, 139.51, 127.47, 126.03, 119.17, 56.66, 49.90, 47.98, 44.62, 39.37, 12.50,
11.9493, -0.0095.
(1S,2S)-2,3-Dihydro-9-{9-fluorenylmethoxycarbonylcarbamoyloxymethyl)6,7-dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (54). To a
solution of alcohol 53 (2.6 mg, 0.00954 mmol) in 0.9 mL dry DCM at - 78 °C was added
Et3N (1 M solution in DCM, 26.61 L, 26.7mol), followed by FmocNCO (0.33 M
solution in CH2Cl2, 65 L, 21.44 mol). After stirring the red solution at -78 °C for 30
min, the cooling bath was removed, and the reaction mixture was allowed to warm to 0
°C for 1 h. 0.9 mL dry CH3CN was added and the reaction mixture was allowed to warm
to rt. After 6 h, the resulting orange solution was concentrated by rotary evaporation, and
the residue was purified by flash chromatography on silica gel (11x5 cm, neat EtOAc
eluent, and then 10:1 CH2Cl2/MeOH eluent 10 mL fractions). Fractions 3-10 gave 2.6 mg
of the product as an orange to red crystals. Analytical TLC on silica gel 60 F254, 10:1
CH2Cl2/MeOH, Rf= 0.45. Molecular ion (M+H+) calcd for C31H28N3O6: 538.1973; found
(electrospray) m/z= 538.1970, error= 1 ppm; 600 MHz NMR (CDCl3, ppm) δ 7.78 (2H,
d, J=7.46 Hz) 7.59 (2 H, d, J=7.46 Hz) 7.42 (2 H, t, J=7.46 Hz) 7.32 (2 H, t, J=7.46 Hz)
7.27 (1 H, s) 5.49 (1 H, d, J=12.08 Hz) 5.38 9 1 H, d, J=12.08 Hz) 4.49 (2 H, d, J=7.10
Hz) 4.36 (1 H, d, J=13.85 Hz) 4.24 ( 1 H, t, J=6.75 Hz) 4.15 ( 1 H, dd, J=13.9, 3.9 Hz)
3.31 (1 H, d, J=4.97 Hz) 2.92 (1 H, dd, J=4.9, 4.4 Hz) 2.4 (3 H, s) 2.039 (3 H, s) 2.095 (3
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H, s) 13C NMR (150 MHz, CDCl3, ppm) δ 183.85, 177.64, 150.71, 150.54, 143.62,
143.27, 143.22, 141.66, 141.32, 139.51, 127.93, 127.19, 125.40, 124.95, 120.10, 111.13,
67.80, 58.56, 50.20, 47.92, 46.64, 44.50, 39.793, 12.35, 11.87, -0.0076.
(1S,2S)-9-Carbamoyloxymethyl-2,3-dihydro-6-methyl-1,2-(N
methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (3). To a solution of 54 (2.4 mg,
4.464, L) in 0.27 mL of anhydrous CH3CN and 0.184 mL of anhydrous CH2Cl2 at rt
was added Et3N (9.2 L, 66.00 mol). After stirring at rt for 7 h, the tan solution was
concentrated by rotary evaporation, and the brown residue was purified by preparative
TLC on silica gel (20x20x0.025 cm, 10:1 CH2Cl2/MeOH eluent) to give 1 mg (71%) of
the product as an orange solid; analytical TLC on silica gel 60 F254, 10:1
CH2Cl2/CH3OH, Molecular ion (M+H+) calcd for C16H18N3O4: 316.1292; found
(electrospray) m/z= 316.1293, error= 0 ppm; 600 MHz NMR (CDCl3, ppm) δ 5.37 (1 H,
AB q, J=12.4 Hz) 5.33 (1 H, AB q, J=12.4 Hz) 4.80-4.55 (2 H, br) 4.37 (1 H, d, J=13.65
Hz) 4.17 (0.55 H, dd, J=13.6, 3.66 Hz) 3.15 ( 1 H, d, J=4.83 Hz) 2.92 (1 H, dd,
J=4.55,4.09 Hz) 2.48 3 H, s) 2.04 (3 H, s) 2.02 (3 H ,s) . 13C NMR (150 MHz, CDCl3,
ppm) δ 183.77, 177.70, 156.81. 142.77, 141.71, 139.36, 127.08, 125.38, 112.82, 57.77,
50.09, 47.85, 44.55, 39.88, 31.93, 29.70, 29.36, 22.69, 14.11, 12.38, 11.84, 1.02, -0.0088.
Solvolysis of the aziridinomitosene 3 in buffered methanolic solutions. General
procedures. The effective "pH" of the methanolic solutions was measured using a
Coming pH Meter 240 equipped with a Coming Ragged Bulb Combo electrode
standardized against aqueous buffer solutions. The solvolysis reactions were carried out
in a 1 mL quartz cuvette (10 mm light path) thermostatted at 20.0±0.5 °C, and were
monitored using a Varian Cary 50 Bio UV-visible spectrophotometer. A 6.34 mM stock
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solution of the AZM 3 (1 mg, 3.171 𝜇mol) was prepared in 500 L of DMSO-𝑑6 and was
stored at -1 5 °C in the freezer. The buffer solutions were prepared using Fisher Scientific
spectrophotometric grade methanol. The first order rate constants were calculated from
the time-dependent decrease of the UV absorption at 480 nm using the Kinetics
Application of Cary WinUV software employing the Marquardt non-linear regression
analysis. Duplicate kinetic runs were performed and the results were averaged.
Methanolysis of the aziridinomitosene 3 at pH 6.0. A kinetic study. A solution
of 0.060 M bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane hydrochloride (BisTris.HCl, 354 mg, 1.44 mmol) and 0.037 M bis(2-hydroxyethyl) iminotris
(hydroxymethyl)methane (Bis-Tris, 184 mg, 0.879 mmol) was prepared in 24 mL of
methanol. The pH of the resulting buffer solution was 6.0±0.1 at 20 °C. The AZM 3 (6.3
mM solution in DMSO- DMSO-𝑑6, 50 L, 0.317 mol) was dissolved in 0.95 mL of the
buffer solution prepared above. The resulting yellow solution was immediately
transferred into a thermostatted (20.0±0.5 °C) cuvette. The UV absorption at 480 nm was
measured every 30 min for a total time of 4500 min yielding the first order rate constant
of 21x10-6 (s-1)A clear yellow solution was formed at the end of the reaction.
Methanolysis of the aziridinomitosene 3 at pH 7.0. A kinetic study. A solution
of 0.055 M bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane hydrochloride (BisTris .HCl, 338 mg, 1.38 mmol) and 0.046 M tris(hydroxymethyl)aminomethane (TRIS,
139 mg, 1.15 mmol) was prepared in 25 mL of methanol. The pH of the resulting buffer
solution was 7.0±0.1 at 20 °C. The AZM 3 (6.3 mM solution in DMSO-𝑑6, 50 L, 0.317
mol) was dissolved in 0.95 mL of the buffer solution prepared above. The resulting
yellow solution was immediately transferred into a thermostatted (20.0±0.5 °C) cuvette.
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The UV absorption at 480 nm was measured every 30 min for a total time of 4500 min
yielding the first order rate constant of 15x10-5 (s-1) A clear yellow solution was formed at
the end of the reaction.
Methanolysis of the aziridinomitosene 3 at pH 8.5. A solution of 0.100 M tris(hydroxymethyl)aminomethane (TRIS, 304 mg, 2.50 mmol) and 0.040 M
tris(hydroxymethyl) aminomethane hydrochloride (TRIS HC1, 160.0 mg, 10.15 mmol)
was prepared in 25 mL of methanol. The pH of the resulting buffer solution was 8.7±0.1
at 20 °C. The AZM 3 (6.3 mM solution in DMSO-𝑑6, 50 L, 0.317 mol) was dissolved
in 0.95 mL of the buffer solution prepared above. The resulting pale yellow solution was
immediately transferred into a thermostatted (20.0±0.5 °C) UV cuvette. No care was
taken to deoxygenate the solution. The UV spectrum was scanned every 30 min for a
total time of 3000 min. A clear, pale yellow solution was formed at the end of the
reaction.
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1H, 13C

Figure

NMR Spectra

Compound Name

NMR

Number
A1
A2
A3
A4
A5
A6
A7

A8

A9

A 10

A 11

A 12

A 13

A 14

Page
Number

4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-2butenoic acid ethyl ester (33).
4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-2butenoic acid ethyl ester (33).
4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-butyric
acid ethyl ester (34).
4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-butyric
acid ethyl ester (34).
5-[3-(tert-Butyldimethylsilyloxy)-1,2dimethylpropyl]-oxazole (35).
5-[3-(tert-Butyldimethylsilyloxy)-1,2dimethylpropyl]-oxazole (35).
2-[(lR,2S) and (lS,2S)-3-Allyloxy-l-hydroxy-2tritylaminopropyl)-5-[(1R) and (1S) , (2R) and (2S)tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (39)
2-[(lR,2S) and (lS,2S)-3-Allyloxy-l-hydroxy-2tritylaminopropyl)-5-[(1R) and (1S) , (2R) and (2S)tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (39)
2-[(2S,3R)-3-Allyloxymethyl-1-trityl-aziridin-2-yl]5-[(1R) and (1S) , (2R) and (2S)- tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(40)
2-[(2S,3R)-3-Allyloxymethyl-1-trityl-aziridin-2-yl]5-[(1R) and (1S) , (2R) and (2S)- tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(40)
2-[(2S,3R)-3-Allyloxymethylaziridin-2-yl]-5-[(1R)
and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy1,2-dimethylpropyl]oxazole (41).
2-[(2S,3R)-3-Allyloxymethylaziridin-2-yl]-5-[(1R)
and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy1,2-dimethylpropyl]oxazole (41).
2-[(2S,3R)-3-Allyloxymethyl-1-methyaziridin-2-yl]5-[(1R) and (1S) , (2R) and (2S)- tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(42).
2-[(2S,3R)-3-Allyloxymethyl-1-methyaziridin-2-yl]5-[(1R) and (1S) , (2R) and (2S)- tert-
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A 15

A 16

A 17

A 18

A 19

A 20

A 21

A 22

A 23

A 24

A 25

A 26

butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(42).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S)-3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2yl)-3-hydroxymethyl-1-methylaziridine (43).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S)-3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2yl)-3-hydroxymethyl-1-methylaziridine (43).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2yl)-3-iodomethyl-1-methylaziridine (44).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2yl)-3-iodomethyl-1-methylaziridine (44).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3hydroxy-1,2-dimethylpropyl]oxazol-2-yl)-3iodomethyl-1-methylaziridine (45).
(2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3hydroxy-1,2-dimethylpropyl]oxazol-2-yl)-3iodomethyl-1-methylaziridine (45).
2S,3R)-3-Iodomethyl-1-methyl-2-(5-[(1R) and (1S),
(2R) and (2S) -1,2-dimethyl-3-oxopropyl]oxazol-2yl)aziridine (46).
2S,3R)-3-Iodomethyl-1-methyl-2-(5-[(1R) and (1S),
(2R) and (2S) -1,2-dimethyl-3-oxopropyl]oxazol-2yl)aziridine (46).
(2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R)
,((1S,2R,3R), (1S,2S,3S) (1R,2S,3S),
(!R,2R,3S),(1S,2S,3R)-3-hydroxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3iodomethyl-1-methylaziridine (47).
(2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R)
,((1S,2R,3R), (1S,2S,3S) (1R,2S,3S),
(!R,2R,3S),(1S,2S,3R)-3-hydroxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3iodomethyl-1-methylaziridine (47).
2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R),
((1S,2R,3R), (1S,2S,3S) (1R,2S,3S),
(1R,2R,3S),(1S,2S,3R)-3-Acetoxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]1023-iodomethyl-1-methylaziridine (48).
2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R),
((1S,2R,3R), (1S,2S,3S) (1R,2S,3S),
(1R,2R,3S),(1S,2S,3R)-3-Acetoxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3iodomethyl-1-methylaziridine (48).
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A 27

A 28

A 29

A 30

A 31

A 32

A 33

A 34

A 35

A 36

A 37

A 38

(1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R)
,((1S,2R,8R), (1S,2S,8S) (1R,2S,8S),
(1R,2R,8S),(1S,2S,8R)-8-Acetoxy-9-(tertbutyldimethylsilyloxymethyl)-2,3,5,6,7,8-hexahydro6,7-dimethyl-1,2-(N-methylaziridino)-5-oxo-1Hpyrrolo[1,2-a]indole (49).
(1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R)
,((1S,2R,8R), (1S,2S,8S) (1R,2S,8S),
(1R,2R,8S),(1S,2S,8R)-8-Acetoxy-9-(tertbutyldimethylsilyloxymethyl)-2,3,5,6,7,8-hexahydro6,7-dimethyl-1,2-(N-methylaziridino)-5-oxo-1Hpyrrolo[1,2-a]indole (49).
(1S,2S,6S,7S) and (1S,2S,6R,7R) (1S,2S,6S,7R) and
(1S,2S,6R,7S)-9-(tert-Butyldimethylsilyloxymethyl)5,8-dioxo-2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2(N-methylaziridino)-1H-pyrrolo[1,2-a]indole (51)
(1S,2S,6S,7S) and (1S,2S,6R,7R) (1S,2S,6S,7R) and
(1S,2S,6R,7S)-9-(tert-Butyldimethylsilyloxymethyl)5,8-dioxo-2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2(N-methylaziridino)-1H-pyrrolo[1,2-a]indole (51)
(1S,2S)-9-(tert-Butyldimethylsilyloxymethyl)-2,3dihydro-6,7-dimethyl-1,2-(N-methylaziridino)-1Hpyrrolo[1,2-a]indole-5,8-dione (52).
(1S,2S)-9-(tert-Butyldimethylsilyloxymethyl)-2,3dihydro-6,7-dimethyl-1,2-(N-methylaziridino)-1Hpyrrolo[1,2-a]indole-5,8-dione (52).
(1S,2S)-2,3-Dihydro-9-hydroxymethyl-6,7-dimethyl1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole5,8-dione (53).
(1S,2S)-2,3-Dihydro-9-hydroxymethyl-6,7-dimethyl1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole5,8-dione (53).
(1S,2S)-2,3-Dihydro-9-{9fluorenylmethoxycarbonylcarbamoyloxymethyl)-6,7dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2a]indole-5,8-dione (54).
(1S,2S)-2,3-Dihydro-9-{9fluorenylmethoxycarbonylcarbamoyloxymethyl)-6,7dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2a]indole-5,8-dione (54).
(1S,2S)-9-Carbamoyloxymethyl-2,3-dihydro-6methyl-1,2-(N methylaziridino)-1H-pyrrolo[1,2a]indole-5,8-dione (3).
(1S,2S)-9-Carbamoyloxymethyl-2,3-dihydro-6methyl-1,2-(N methylaziridino)-1H-pyrrolo[1,2a]indole-5,8-dione (3).
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Figure A1.

1H

NMR spectrum of 4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-2butenoic acid ethyl ester (33).
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Figure A2.

13C

NMR of 4-(tert-Butyldimethylsilyloxy)-2, 3-dimethyl-2-butenoic
acid ethyl ester (33).
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Figure A3.

1H

NMR spectrum of 4-(tert-Butyldimethylsilyloxy)-2, 3-dimethylbutyric acid ethyl ester (34).
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Figure A4.

13C

NMR spectrum of 4-(tert-Butyldimethylsilyloxy)-2, 3-dimethylbutyric acid ethyl ester (34).
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Figure A5.

1H

NMR spectrum of 5-[3-(tert-Butyldimethylsilyloxy)-1,2dimethylpropyl]-oxazole (35).
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Figure A6.

13C

NMR of 5-[3-(tert-Butyldimethylsilyloxy)-1,2-dimethylpropyl]oxazole (35).
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Figure A7. 1H NMR spectrum of 2-[(lR,2S) and (lS,2S)-3-Allyloxy-l-hydroxy-2tritylaminopropyl)-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (39)
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Figure A8. 13C NMR spectrum of 2-[(lR,2S) and (lS,2S)-3-Allyloxy-l-hydroxy-2tritylaminopropyl)-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (39)
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Figure A9. 1H NMR spectrum of 2-[(2S,3R)-3-Allyloxymethyl-1-trityl-aziridin-2yl]-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (40)
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Figure A10. 13C NMR spectrum of 2-[(2S,3R)-3-Allyloxymethyl-1-trityl-aziridin-2yl]-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (40)
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Figure A11. 1H NMR spectrum of 2-[(2S,3R)-3-Allyloxymethylaziridin-2-yl]-5[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(41).
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Figure A12. 13C NMR spectrum of 2-[(2S,3R)-3-Allyloxymethylaziridin-2-yl]-5[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazole
(41).
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Figure A13. 1H NMR spectrum of 2-[(2S,3R)-3-Allyloxymethyl-1-methyaziridin-2yl]-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (42).
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Figure A14. 13C NMR spectrum of 2-[(2S,3R)-3-Allyloxymethyl-1-methyaziridin-2yl]-5-[(1R) and (1S) , (2R) and (2S)- tert-butyldimethylsilyloxy-1,2dimethylpropyl]oxazole (42).
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Figure A15. 1H NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S)-3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2-yl)-3-hydroxymethyl-1methylaziridine (43).
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Figure A16. 13C NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S)-3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2-yl)-3-hydroxymethyl-1methylaziridine (43).
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Figure A17. 1H NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3-tertbutyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1methylaziridine (44).
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Figure A18. 13C NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3tert-butyldimethylsilyloxy-1,2-dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1methylaziridine (44).
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Figure A19. 1H NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3hydroxy-1,2-dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1-methylaziridine (45).
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Figure A20. 13C NMR spectrum of (2S,3R)-2-(5-[(1R) and (1S), (2R) and (2S) -3hydroxy-1,2-dimethylpropyl]oxazol-2-yl)-3-iodomethyl-1-methylaziridine (45).
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Figure A21. 1H NMR spectrum of 2S,3R)-3-Iodomethyl-1-methyl-2-(5-[(1R) and
(1S), (2R) and (2S) -1,2-dimethyl-3-oxopropyl]oxazol-2-yl)aziridine (46).
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Figure A22. 13C NMR spectrum of 2S,3R)-3-Iodomethyl-1-methyl-2-(5-[(1R) and
(1S), (2R) and (2S) -1,2-dimethyl-3-oxopropyl]oxazol-2-yl)aziridine (46).
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Figure A23. 1H NMR spectrum of (2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R)
,((1S,2R,3R), (1S,2S,3S) (1R,2S,3S), (!R,2R,3S),(1S,2S,3R)-3-hydroxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1-methylaziridine
(47)
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Figure A24. 13C NMR spectrum of (2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S),
(1R,2S3R) ,((1S,2R,3R), (1S,2S,3S) (1R,2S,3S), (!R,2R,3S),(1S,2S,3R)-3-hydroxy-1,2dimethyl-6-tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1methylaziridine (47).
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Figure A25. 1H NMR spectrum of 2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R),
((1S,2R,3R), (1S,2S,3S) (1R,2S,3S), (1R,2R,3S),(1S,2S,3R)-3-Acetoxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1-methylaziridine
(48).
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Figure A26. 13C NMR spectrum of 2S,3R)-2-[5-[(1R,2R,3R), (1R,2R,3S), (1R,2S3R),
((1S,2R,3R), (1S,2S,3S) (1R,2S,3S), (1R,2R,3S),(1S,2S,3R)-3-Acetoxy-1,2-dimethyl-6tert-butyldimethylsilyloxy-4-hexynyl]oxazol-2-yl]-3-iodomethyl-1-methylaziridine
(48).
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Figure A27. 1H NMR spectrum of (1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R)
,((1S,2R,8R), (1S,2S,8S) (1R,2S,8S), (1R,2R,8S),(1S,2S,8R)-8-Acetoxy-9-(tertbutyldimethylsilyloxymethyl)-2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2-(Nmethylaziridino)-5-oxo-1H-pyrrolo[1,2-a]indole (49).
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Figure A28. 13C NMR spectrum of (1S,2S, -[(1R,2R,8R), (1R,2R,8S), (1R,2S,8R)
,((1S,2R,8R), (1S,2S,8S) (1R,2S,8S), (1R,2R,8S),(1S,2S,8R)-8-Acetoxy-9-(tertbutyldimethylsilyloxymethyl)-2,3,5,6,7,8-hexahydro-6,7-dimethyl-1,2-(Nmethylaziridino)-5-oxo-1H-pyrrolo[1,2-a]indole (49).
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Figure A30. 3C NMR spectrum of (1S,2S,6S,7S) and (1S,2S,6R,7R) (1S,2S,6S,7R)
and
(1S,2S,6R,7S)-9-(tert-Butyldimethylsilyloxymethyl)-5,8-dioxo-2,3,5,6,7,8hexahydro-6,7-dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole (51)
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Figure A31. 1H NMR spectrum of
(1S,2S)-9-(tertButyldimethylsilyloxymethyl)-2,3-dihydro-6,7-dimethyl-1,2-(N-methylaziridino)-1Hpyrrolo[1,2-a]indole-5,8-dione (52).
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Figure A32. 13C NMR spectrum of (1S,2S)-9-(tert-Butyldimethylsilyloxymethyl)2,3-dihydro-6,7-dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione
(52).
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Figure A33. 1H NMR spectrum of (1S,2S)-2,3-Dihydro-9-hydroxymethyl-6,7dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (53).
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Figure A34. 13C NMR spectrum of (1S,2S)-2,3-Dihydro-9-hydroxymethyl-6,7dimethyl-1,2-(N-methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (53).
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Figure A35. 1H NMR spectrum of
(1S,2S)-2,3-Dihydro-9-{9fluorenylmethoxycarbonylcarbamoyloxymethyl)-6,7-dimethyl-1,2-(Nmethylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (54).
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Figure A36. 13C NMR spectrum of
(1S,2S)-2,3-Dihydro-9-{9fluorenylmethoxycarbonylcarbamoyloxymethyl)-6,7-dimethyl-1,2-(Nmethylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (54).
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Figure A4. 13C NMR spectrum of

Figure A37. 1H NMR spectrum of (1S,2S)-9-Carbamoyloxymethyl-2,3-dihydro-6methyl-1,2-(N methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (3).
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Figure A38. 13C NMR spectrum of (1S,2S)-9-Carbamoyloxymethyl-2,3-dihydro-6methyl-1,2-(N methylaziridino)-1H-pyrrolo[1,2-a]indole-5,8-dione (3).
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APPENDIX B
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UV Spectra
Figure Number

Methanolysis of Aziridinomitosene 3

Page Number

B1……………...

UV-Vis spectrum of Methanolysis of AZM 3 at
pH 6.0 over 4500 Minutes
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B2……………...

UV-Vis spectrum of methanolysis of AZM 3 at
pH 7.0 over 4500 Minutes

114

B3……………...

UV-Vis absorbance at 480 nm over 4500 minutes
(methanolysis of AZM 3 at pH 7.0)

115

B4……………...

UV-Vis spectrum of methanolysis of AZM 3 at
pH 8.7 over 300 Minutes
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Figure B1.

UV-Vis spectrum of Methanolysis of AZM 3 at pH 6.0 over 4500
Minutes
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Figure B2.

UV-Vis spectrum of methanolysis of AZM 3 at pH 7.0 over 4500
Minutes
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480 nm

Figure B3.

UV-Vis absorbance at 480 nm over 4500 minutes (methanolysis of
AZM 3 at pH 7.0)

115

Figure B4.

UV-Vis spectrum of methanolysis of AZM 3 at pH 8.7 over 300
Minutes

